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Abstract 
 
Background 
Use of blood glucose test strips has dramatically increased over the past two decades in Saskatchewan 
and has emerged as a major health care expenditure. Although regular self-monitoring of blood glucose 
using test strips is imperative in certain patient groups, there is no strong evidence for clinical benefit in 
the majority of patients with diabetes. As a result, public and private payers have begun to limit the 
quantity of test strips eligible for reimbursement under drug benefit plans.  The majority of literature 
supporting self-monitoring of blood glucose focuses on improvements in glycemic control.  Self-
monitoring of blood glucose may also be used to detect hypoglycemia, but the relationship between test 
strip use and hypoglycemic events has not been well studied.  Thus, the purpose of this study was to 
determine the relationship between blood glucose test strip use and hypoglycemia-related healthcare 
utilization. 
Methods 
Hypoglycemia endpoints and test strip utilization among beneficiaries of the Saskatchewan Drug Plan 
were described using Saskatchewan’s administrative health databases from 1996 to 2014. A time-series 
analysis using generalized estimating equations was conducted to test the association between 
hypoglycemia hospitalizations and utilization of blood glucose test strips at a population level. A 
nested case-control study was conducted within a cohort of patients with diabetes using a conditional 
logistic regression model to determine if individual risk of hospitalization for hypoglycemia was lower 
among patients who used blood glucose test strip compared to those who do not. 
Results 
A total of 5,166 hospitalizations for hypoglycemia were recorded during the study period.  The average 
crude rate of hospitalization for hypoglycemia was 26.2 admissions per 100,000.  No consistent trend 
in hypoglycemia hospitalizations was evident.  All measures of blood glucose test strip use increased 
over the study period.  After controlling for health care utilization and changes in population size, the 
number of test strips dispensed was not associated with a significant change in the rate of 
hospitalization for hypoglycemia  (p=0.41).  Due to substantial clinical differences between cases and 
controls, modeling was not conducted in the overall cohort of diabetic patients.  Instead, two subgroups 
were created to represent those at highest (i.e. patients using insulin) and lowest (i.e. patients using low 
risk oral hypoglycemic agents) risk of developing drug-induced hypoglycemia. After controlling for 
confounders, blood glucose test strip use was not associated with hospitalization for hypoglycemia in 
insulin users [adjusted OR 1.08; 95% CI (0.88,1.31); p=0.48], or in low risk oral hypoglycemic users 
[adjusted OR 1.04; 95% CI (0.55,1.94); p=0.91]. 
Discussion 
Blood glucose test strip use was not associated with hospitalization for hypoglycemia in both 
population and individual level analyses.  These findings were consistent among those at high risk and 
low risk of developing drug-induced hypoglycemia.  This research adds to the existing body of 
literature suggesting that policies limiting blood glucose test strip reimbursement in patients not on 
insulin are unlikely to be detrimental to patient safety.  
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Chapter 1: Introduction 
Diabetes is a metabolic disorder characterized by persistently elevated blood glucose levels 
(hyperglycemia)[1, 2].  Approximately 7 % of Canadians have been diagnosed with diabetes and its 
prevalence continues to increase [3].  Individuals who suffer from diabetes are at risk of both 
immediate complications of hyperglycemia as well as long-term comorbidities, such as cardiovascular 
disease (including stroke), kidney disease, blindness, and amputation[2].  Current management of 
diabetes involves using pharmacologic therapies to lower blood glucose to guideline recommended 
targets, which are chosen to minimize complications of hyperglycemia.   
Patients with diabetes can easily monitor their own blood glucose levels using testing strips, 
which provide an immediate estimation of blood glucose concentration to the user [4, 5].  As a result, 
self-monitoring of blood glucose (SMBG) has become a common strategy to engage patients in the 
process of achieving blood glucose targets and to minimize the risk of drug-induced hypoglycemia [1, 
2].  Indeed, current evidence suggests that routine SMBG is imperative in certain diabetic patient 
populations such as those using high doses of insulin [2, 6].  However, SMBG does not appear to 
benefit all patients with diabetes.  In fact, it may be unnecessary in individuals at low risk of 
developing hypoglycemia [7, 8].  
SMBG has been associated with improved glycemic control in patients receiving non-insulin 
medications, but the degree of benefit is too small to be of any clinical significance and is not likely to 
translate into improvements in long-term outcomes or quality of life [7-9].  Moreover, no evidence can 
be found to support the use of SMBG for preventing drug-induced hypoglycemia in low-risk patients.  
However, it is theoretically possible that patients employing SMBG may be able to detect and 
subsequently self-treat episodes of drug-induced hypoglycemia in a timely fashion, thereby avoiding 
the need to present to healthcare services for treatment.  In this case, higher use of blood glucose testing 
strips in the population would be expected to reduce hospitalizations due to hypoglycemia.  To our 
knowledge, the relationship between population-wide use of blood glucose test strips and hospital 
admissions for hypoglycemia has never been examined.           
The use of blood glucose testing strips is a major health care expenditure.  In 2012, public and 
private drug plans in Canada spent an estimated $503 million on test strips alone, with $393 million of 
that attributed to patients who were not using insulin[7, 9].  In Saskatchewan, at least 50% of the costs 
of test strips are paid by the provincial drug plan[10].  Numerous provinces and federal payers have 
already imposed restrictions on the number of strips that are available as a benefit to patients with 
2 
diabetes that are not on insulin.  Given the high cost of hospital inpatient treatment for hypoglycemia 
and the potential demands placed on emergency departments for acute events, an examination of the 
impact of SMBG and its role in healthcare utilization seems prudent.   
 The aim of this research is to determine if relationships exist between blood glucose test strip 
utilization and rates of hypoglycemia at the population level, and to explore the impact of blood 
glucose test strip use on the risk of being hospitalized for hypoglycemia. 
 
Objective 1: To determine if utilization of blood glucose test strips at the provincial level result in 
lower rates of hospitalizations for hypoglycemia. 
Objective 2: To determine if the individual risk of hospitalization for hypoglycemia is lower among 
patients who use blood glucose test strips compared to those who do not.  
 
 
Chapter 2: Literature Review 
 
Diabetes mellitus 
Hyperglycemia is the primary manifestation of diabetes mellitus resulting from an absolute or 
relative insulin deficiency [2, 3].   Two distinct subtypes typically distinguish the disease[3].  Type 1 
diabetes is caused by autoimmune destruction of pancreatic β-cells, which results in an absolute 
deficiency in insulin secretion [1].  Type 1 diabetes is diagnosed in younger patients and accounts for 
5-10% of the total burden of diabetes in Canada [2, 3].  In contrast, type 2 diabetes accounts for the 
vast majority of cases and is characterized by insulin resistance[1], typically being diagnosed in older 
patients [3].  Other types of diabetes, such as gestational diabetes (i.e. diabetes during pregnancy) and 
drug-induced diabetes can also occur in select patient populations [1]. 
 
Pharmacologic Management 
For individuals with type 1 diabetes, insulin is a lifesaving therapy started immediately at diagnosis 
[2]. Insulin is administered by subcutaneous injection or continuous subcutaneous infusion. Although 
initially isolated from animal sources (i.e. bovine or porcine derived insulin), modern insulin is 
manufactured using recombinant DNA technology to produce structurally identical human insulin or 
modified insulin analogues[2].  Insulins are categorized based on their duration of action and their time 
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to onset and peak effect.  
Patients with type 1 diabetes are usually treated with multi-dose or basal-bolus insulin regimens in 
an attempt to mimic normal pancreatic insulin secretion [2].  For example, basal insulin levels are 
mimicked through the administration of an intermediate or long-acting insulin preparation (or insulin 
analogue) administered once or twice daily.  Bolus or prandial insulin levels are mimicked by 
administering short- or rapid-acting insulin (or insulin analogue) at meal times.  The exact dose of 
prandial insulin depends on several factors including the carbohydrate content of each meal, the 
glycemic index of the meal consumed, and the amount of physical activity or exercise around 
mealtimes [2].  Additional doses of short-acting/rapid-acting insulin analogues may also be used 
throughout the day to correct hyperglycemia [2].  Individuals diagnosed with type 1 diabetes must 
undergo significant education regarding insulin injections, dose titration based on diet and physical 
activity, sick-day management, avoidance of hypoglycemia, and management of hyperglycemia in 
order to effectively self-manage their condition[2].  Obviously, SMBG is an integral part of the 
successful management of this condition.   
In contrast to those with type 1 diabetes, patients with type 2 diabetes form a much more 
heterogeneous group [11].  Pharmacologic treatment of type 2 diabetes varies significantly based on the 
duration and progression of the disease [2].  Type 2 diabetes is characterized initially by insulin 
resistance (i.e. relative insulin deficiency) but develops into an absolute insulin deficiency as pancreatic 
β-cell function declines over time [12].  Initially, some patients may be able to manage type 2 diabetes 
through lifestyle modifications (i.e. weight loss, dietary modifications, and increased physical activity), 
however the progressive nature of the disease will likely require pharmacologic therapy to be initiated 
when glycemic targets cannot be met through lifestyle interventions alone [1, 2].  Choice of 
pharmacologic therapy in patients with type 2 diabetes depends on the degree of hyperglycemia at 
diagnosis, the presence of microvascular or macrovascular complications, risk for developing 
hypoglycemia, concomitant medical conditions, medication side effects, the ability of the patient to 
self-manage, and patient preference [2].   
Unlike the treatment of type 1 diabetes, type 2 diabetes may be managed using oral hypoglycemic 
agents as well as insulin.  Oral hypoglycemic agents are categorized according to their mechanisms of 
action.  They may increase pancreatic secretion of insulin (insulin secretagogues), decrease hepatic 
glucose production and/or increase sensitivity to insulin (biguanides and thiazolidiazones), block or 
delay uptake of dietary carbohydrates (alpha-glucosidase inhibitors), or mimic or enhance incretin 
secretion (GLP-1 agonists and DPP-4 inhibitors) [1].   
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Drug therapy is typically initiated using a single oral hypoglycemic agent, unless severe 
hyperglycemia and/or metabolic decompensation is present, in which case a combination of oral 
hypoglycemics or insulin may be initiated [1, 2].  Dosing of oral agents may be titrated to achieve 
target blood glucose levels, although combinations of different oral agents at submaximal doses have 
increased efficacy and reduced side effects as compared to maximal doses of single agents alone[2].  
Insulin may be started at any time in the treatment of type 2 diabetes, but is typically reserved for 
patients receiving maximal doses of oral hypoglycemics and unable to meet glycemic targets, or for 
those with end-organ damage (i.e. end-stage renal disease), which renders oral hypoglycemics 
clinically inappropriate [1, 2].  Insulin also may be used in combination with oral hypoglycemics.  The 
combination results in lower insulin doses that are able to effectively manage blood glucose levels, but 
with less weight gain and decreased risk of hypoglycemia when compared to insulin use alone [1].  
Insulin therapy in patients with type 2 diabetes may be initiated as a once daily injection of a long-
acting preparation or analogue in combination with oral hypoglycemic agents or as a basal-bolus 
regimen (in which case oral hypoglycemics are typically discontinued)[2]. 
 
Treatment Goals 
Results of the Diabetes Control and Complications Trial (DCCT) were used to establish current 
management strategies and treatment goals in patients with type 1 diabetes. The DCCT was a multi-
center, randomized clinical trial designed to compare intensive insulin therapy versus conventional 
diabetes therapy on the development and progression of microvascular complications of diabetes in 
1,441 type 1 diabetic patients [13]. The conventional therapy arm administered insulin injections once 
or twice daily (along with once daily SMBG or urine glucose monitoring) with the main goal of 
therapy being the absence of symptoms attributed to hyperglycemia.  The intensive therapy arm 
administered insulin injections three or more times daily (along with SMBG at least 4 times per day) 
titrated to achieve a pre-prandial (fasting) plasma glucose level of 3.9-6.7 mmol/L and a hemoglobin 
A1c (HbA1c) of 6.05% or less.  After a mean 6.5 years follow-up, intensive therapy was associated 
with significantly lower hemoglobin A1c and plasma glucose profiles, a 76% risk reduction in 
development of primary retinopathy and 54% risk reduction in the progression of secondary 
retinopathy, and a reduction in nephropathy and neuropathy[13]. 
Numerous trials have examined the optimal level of glycemic control in patients with type 2 
diabetes.  The UK Prospective Diabetes Study (UKPDS) was designed to determine if intensive blood 
glucose control reduces the risk of micro- and macrovascular complications in patients newly 
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diagnosed with type 2 diabetes [14].  Subjects were assigned to receive either conventional therapy or 
intensive therapy.  The conventional therapy arm aimed to achieve a fasting plasma glucose level of 
less than 15 mmol/L through dietary interventions, while avoiding symptoms of hyperglycemia.  The 
intensive therapy arm aimed to achieve a fasting plasma glucose level of less than 6 mmol/L and 
received pharmacologic therapy with either insulin or sulfonylureas [14]. In the conventional arm, 
fasting plasma glucose and HbA1c increased steadily over the ten years after randomization.  In the 
intensive arm, there was an initial decrease in fasting plasma glucose and HbA1c in the first year, 
followed by an increase in both fasting glucose and HbA1c similar to that seen in the conventional arm.   
The median HbA1c over ten years was 7.0% in the intensive arm, as compared to 7.9% in the 
conventional arm (p<0.001).  The intensive arm showed a significant 25% relative risk reduction in 
microvascular endpoints compared with the conventional treatment group, which was primarily due to 
decreased retinal photocoagulation in the intensive arm. There was also a trend towards a reduction in 
myocardial infarction in the intensive arm (p=0.052), but no significant difference was noted between 
the two arms for diabetes-related mortality and all-cause mortality [14]. 
 The Action to Control Cardiovascular Risk in Diabetics (ACCORD) trial attempted to 
determine if intensive diabetes therapy (with the goal of achieving a ‘normal’ HbA1c of <6.0%) 
reduced cardiovascular events in patients with type 2 diabetes and cardiovascular disease or risk factors 
for cardiovascular disease [15].  The trial was stopped after 3.5 years due to a 22% increase in all-cause 
mortality in the intensive diabetes therapy arm (HR 1.22; 95% CI [1.01,1.46], p<0.04). Also, there was 
no significant decrease in cardiovascular events between the control and intensive arms with an event 
rate of 6.9% per year in the intensive arm and 7.2% in the control arm (HR 0.90, 95% CI [0.78,1.02]; 
p= 0.16)[15].  In this population of high cardiovascular risk diabetic patients, intensive blood glucose 
lowering did not reduce cardiovascular events as originally postulated and actually increased the risk of 
adverse outcomes, including weight gain, hypoglycemia, and death[15]. 
 The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release 
Controlled Evaluation (ADVANCE) trial also sought to assess the effects of intensive glycemic control 
in type 2 diabetics [16].  The intervention arm was able to achieve an HbA1c of 6.5% (compared to 7.3 
% in the control arm), which was associated with a significant reduction in major microvascular events 
primarily due to a protective effect against nephropathy[16].  However, no significant differences were 
observed in the number of macrovascular events or deaths despite achieving a similar degree of HbA1c 
reduction as in ACCORD.  Although there was no significant reduction in the development of 
retinopathy, the ADVANCE trial provides some additional evidence for benefits of intensive glycemic 
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control in reducing the risk of microvascular complications, despite no significant macrovascular 
benefit associated with intensive glycemic control. 
Based on the evidence obtained from the aforementioned landmark trials, along with 
epidemiological data, the benefit conferred from intensive glycemic control varies according to the type 
of patient and treatment [2, 13, 15, 16].  Current Diabetes Canada (DC) guidelines recommend that 
glycemic targets should be individualized based on age, duration of disease, presence of comorbidities 
(especially cardiovascular disease), life expectancy, and risk of hypoglycemia [2].  In most patients 
with type 1 and type 2 diabetes, a target HbA1c of ≤7.0% is considered optimal in order to reduce the 
risk of microvascular complications. In selected patients, a more stringent HbA1c of ≤6.5% may be 
considered to further reduce risk of microvascular complications, however this must be balanced 
against an increased risk of hypoglycemia.  In older patients with limited life expectancy or functional 
dependency, or in those with significant cardiovascular disease, a history of severe hypoglycemia 
and/or hypoglycemia unawareness, less aggressive HbA1c targets (i.e. 7.1%- 8.5%) may be considered 
[2]. 
 
Monitoring of glycemic control 
Monitoring of glycemic status is fundamental to diabetes management as it enables an assessment 
of treatment efficacy and guides therapeutic adjustment to achieve glycemic targets[17].  In most 
patients, glycosylated hemoglobin (hemoglobin A1c or HbA1c) is a reliable measure of blood glucose 
concentrations over the preceding 90-120 days[2].  Current guidelines recommend measuring HbA1c 
every 3-6 months, depending on the patient’s proximity to glycemic targets[2].  Results may be used by 
health care providers to assess mean glycemia, and as a measure of risk for developing long-term 
diabetic complications[17].   
In contrast to HbA1c, which is typically performed and interpreted by health-care providers, self-
monitoring of blood glucose is the measurement of blood glucose concentrations by patients with 
diabetes in their home environment [5].  The ultimate goal of self-monitoring of blood glucose is to 
collect blood glucose information at a number of different time points to construct a blood glucose 
profile which can then be used to create or modify a therapeutic regimen to optimize blood glucose 
control[18].  Self-monitoring can also be used by patients to help titrate medication dosing (e.g. 
insulin), detect or confirm hyper- and hypoglycemia, and to assess the effects of diet and lifestyle 
choices on their blood glucose levels [5, 18].  SMBG may also have a role in promoting patient 
empowerment as it may increase patients’ ability to independently manage their disease, provide 
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motivation to remain adherent to therapy, or make healthy lifestyle choices [19].    
Blood glucose self-monitoring technology is relatively recent, having only been utilized in the 
management of diabetes since the mid 1980's [17]. Prior to the availability of blood glucose testing 
strips, diabetes therapy was titrated to produce symptom relief (i.e. polydipsia, polyuria, and nocturia) 
rather than achieve specific blood glucose targets[17].  The first quantitative and semi-quantitative 
urine and blood glucose assays were difficult to interpret and therefore not suitable for home testing 
[4]. The first blood glucose meters required great precision to operate and were too cumbersome to be 
considered suitable for individual use[4].  As a result, the majority of blood glucose testing continued 
to be conducted in physician offices or other health care settings.  Further improvements on these initial 
models decreased their size, improved their precision, and ultimately resulted in an end-product 
suitable for most patients to reliably measure their blood glucose at home[4].  
Current blood glucose meters are palm-sized, equipped with a digital display and use test strips that 
are specific to the type of meter [4, 5]. Patients prick the skin (usually on the tip of the finger) using a 
lancet device to produce a small amount of blood that is applied to the test strip, which is inserted into 
the glucose meter. The concentration of glucose in the blood is quantified by a photometer and an 
output reading is provided to the user, usually within 30 seconds. The results can be stored in the 
device’s digital memory for retrieval at a later time.  Most modern meters are user-friendly, include 
alerts to warn of hypo- or extreme hyperglycemia, and may have additional software to allow 
individuals to record diet and exercise patterns to aid in interpreting blood glucose patterns [4, 17]. The 
test strip method is presently the only means by which an individual may accurately self-monitor their 
blood glucose concentrations [5].  It is worth noting that self-monitoring of blood glucose itself does 
not produce any meaningful clinical outcomes unless it is accompanied by changes in behaviors in 
response to blood glucose readings [5]. 
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Trends in blood glucose test strip utilization 
Blood glucose strips are emerging as a major source of health-care expenditure across the country.   
In a recent report of evidence based drug therapy, British Columbia identified a significant increase in 
test strip usage from 1996-2009. In 2009, total spending for blood glucose test strips was reported at 
$50 million, with an estimated $25 million attributed to test strip use in patients with type 2 
diabetes[20]. In Ontario, blood glucose test strips represented the third largest expenditure to Ontario 
public drug plans, costing over $100 million and comprising 3.3% of total drug expenditures between 
2007 and 2008 [21]. 
Test strip usage in Saskatchewan has also increased dramatically over the last two decades.   In 
2015, the Saskatchewan Drug Utilization and Outcomes Research Team (SDUORT) described trends 
and utilization patterns of test strip usage using Saskatchewan’s administrative databases.   In 1996, the 
crude number of strips dispensed was over 3.5 million attributed to 20,223 unique patients.  In 2013, 
this increased to 16.8 million among 55,506 unique patients [10].  In each calendar year, approximately 
20% of all test strip users had no record of blood glucose lowering medication use.  An additional 26% 
of test strip users were receiving only oral hypoglycemic drugs with a low risk of causing 
hypoglycemia[10] .  The total cost of strips increased from $3.5 million in 1996 to $16.8 million in 
2013, of which the Saskatchewan government cost share was approximately $9 million[10] .  
A significant portion of test strip use in Saskatchewan is in patients who do not appear to benefit 
greatly from SMBG [10].  In October 2015, the Saskatchewan government limited the quantity of 
blood glucose test strips covered for patients not on insulin [22].  Prior to this date, patients in 
Saskatchewan were able to receive up to 900 strips every 3 months, regardless of their clinical situation 
[10, 22].    
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Evidence for the use of SMBG in Diabetes Mellitus 
 
Glycemic Control 
For those with type 1 diabetes, the benefits of intensive glucose control (i.e. maintaining normal 
or near-normal blood glucose levels) have been well documented in clinical trials [13].   However, 
while intensive glycemic control was associated with improved clinical outcomes such as decreases in 
HbA1c and microvascular complications, patients in the intensive arm of the DCCT also experienced a 
three-fold increase in episodes of severe hypoglycemia and coma [13].   As such, Canadian and 
American diabetes guidelines recommend frequent self-monitoring of blood glucose in this patient 
population [2, 6] to minimize the risk of drug-induced hypoglycemia. 
Patients treated with intensive insulin regimens should perform SMBG at least 3 times per day, at 
different times per day (i.e. pre- and post-prandial, prior to exercise, at bedtime, prior to driving, if 
hypoglycemia is suspected) depending on the specific needs of the individual [2, 6].  Many of the 
major trials that have demonstrated the benefit of intensive glycemic control [13, 23] included SMBG 
as a component of the intervention arm, suggesting that SMBG is an important component of effective 
diabetes management [6, 24]; however, the direct effects of SMBG have rarely been studied in 
randomized trials [24].  The Canadian Optimal Medication Prescribing and Utilization Service 
(COMPUS) conducted a systematic review and meta-analysis to determine the efficacy, safety, and 
optimal frequency of SMBG in type 1, type 2, and gestational diabetes. They determined that few 
studies have explored the optimal frequency of SMBG in patients with insulin-treated diabetes (type 1 
or type 2).  Based on low quality clinical data, the reviewers concluded that SMBG was associated with 
improvements in glycemic control [7].  None of the randomized studies in type 1 diabetes reported 
hypoglycemia as an outcome [7] and only one study reported hypoglycemia outcomes in type 2 
diabetic patients using insulin [7].  However, despite the lack of robust clinical evidence, self-
monitoring of blood glucose is considered the standard of care for patients who use insulin [7, 24].  
Patients who are not treated with insulin do not typically titrate oral hypoglycemic agents in 
response to SMBG readings, although they may use blood glucose levels to adjust other health 
behaviors (i.e. diet and physical activity) [8].  As such, the efficacy of self-monitoring of blood glucose 
in patients with non-insulin treated type 2 diabetes has been the subject of considerable debate, 
generating numerous studies, systematic reviews, and meta-analyses. The 2009 systematic review and 
meta-analysis conducted by COMPUS pooled results from seven randomized controlled trials in non-
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insulin treated patients.  They reported a “statistically significant, albeit clinically modest” reduction in 
HbA1c of -0.25% (95% CI [-0.36, -0.15]) associated with SMBG (versus no SMBG) [7].  In subjects 
with worse glycemic control at baseline (i.e. HbA1c greater than 8%), subjects performing SMBG had 
greater improvements in HbA1c than those who did not perform SMBG [7].  The effect of SMBG on 
HbA1c was similar regardless of the intensity of patient education, which is contrary to the commonly 
held assumption that SMBG should be more effective with patient education and training [7]. 
A more recent review was published in 2012 by the Cochrane Collaboration to assess the effects of 
SMBG in patients with type 2 diabetes not using insulin [25].  Their primary outcomes were effects on 
glycemic control (as measured by HbA1c), health-related quality of life, and patient satisfaction in 
trials comparing SMBG based interventions with no SMBG (control) [8].  In trials that examined 
patients with diabetes duration greater than one year, SMBG was associated with a statistically 
significant reduction in HbA1c of 0.3% (95% CI [-0.4%, -0.1%]) within six months of follow-up.  
However, the benefit of SMBG on glycemic control appeared to be short-term, as trials with 6-12 
months of follow up were associated with a non-significant decrease of 0.1% in HbA1c [8].  In newly 
diagnosed diabetic patients (i.e. disease duration less than 1 year), SMBG was associated with a 
significant 0.5% reduction in HbA1c, suggesting potential for clinical benefit in this patient population.  
However, the use of SMBG was not associated with any appreciable benefit on patient indices of well-
being, treatment satisfaction, or health-related quality of life [8]. 
The evidence summarized in these reviews suggests that the effect of SMBG on glycemic control is 
small in patients not using insulin.  There does seem to be evidence of benefit in certain patient 
subgroups, most notably in patients newly diagnosed with diabetes, and in those with poor metabolic 
control.  However, SMBG did not increase patient treatment satisfaction, well-being indices, or other 
measures of self-care[7, 8]. 
Current North American guidelines do not provide clear recommendations on SMBG for 
diabetic patients not on insulin. The DC guidelines recommend that SMBG should be individualized 
for those on oral hypoglycemics and should be considered when glycemic targets are not being met, 
along with patient and provider education [2].  DC guidelines suggest that testing 1-2 times per week 
should suffice in most patients; however this may be increased in individuals who are at higher risk for 
hypoglycemia.  Although recommending SMBG in patients at risk for hypoglycemia is clinically 
intuitive, it has not been supported by evidence in randomized trials [26-28].  
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Hypoglycemia 
Drug-induced hypoglycemia (i.e., abnormally low plasma glucose) is the most common 
complication of diabetes management [2, 12, 29].  Drug-induced hypoglycemia occurs much more 
frequently in patients with type 1 diabetes than in those with type 2 diabetes, primarily due to the use of 
insulin [11, 12, 29-33].  The severity of hypoglycemia is clinically defined according to the patient’s 
ability to independently manage the condition [2, 13, 30].  In mild to moderate hypoglycemia, patients 
are usually able to self-treat with administration of an oral carbohydrate [2].  Symptoms of mild 
hypoglycemia are typically autonomic (i.e. hunger, palpitations, sweating, trembling, anxiety) while 
moderate hypoglycemia may result in neuroglycopenic symptoms (i.e. drowsiness and confusion) in 
addition to autonomic symptoms [2, 11].  Severe hypoglycemia may result in extreme confusion, 
seizure, or coma, and requires third-party assistance or medical intervention for treatment and recovery 
[2, 11, 32, 34, 35]. If untreated, severe hypoglycemia can result in death; 2-4% of deaths in patients 
with type 1 diabetes have been associated with hypoglycemia [36].   
Rates of overall hypoglycemia in patients with type 1 diabetes may range as high as 115 to 320 
per 100 patient years [30, 34, 37].  Hypoglycemia in patients with type 2 diabetes has been reported to 
occur at rates of 35 to 70 events per 100 patient years [30, 34, 37].  However, the incidence of 
hypoglycemia in type 2 diabetes may approach that of type 1 in those with a long duration of disease or 
who are receiving intensive insulin therapy [12, 32, 34, 37].  Patients with an increased risk for severe 
hypoglycemia include those with prior episodes of hypoglycemia, hypoglycemia unawareness, a long 
duration of insulin therapy, and/or long duration of disease [29, 33, 38].  In patients with type 2 
diabetes increasing age, cognitive impairment, higher HbA1c and low health literacy have also been 
associated with an increased risk of hypoglycemia [2, 29]. 
In individuals without diabetes, decreasing blood glucose levels will trigger a predictable 
physiologic response to quickly correct or prevent hypoglycemia from occurring [12].  Endogenous 
insulin secretion is reduced, while glucagon and epinephrine secretion increase in order to stimulate 
hepatic glycogenlysis and gluconeogenesis, and decrease skeletal muscle uptake of glucose [12].  In 
those with type 1 diabetes, the secretion of these counter-regulatory hormones is impaired. In patients 
with type 2 diabetes, the normal physiologic response to low blood glucose is preserved early in the 
course of the disease [12].  However, the progressive nature of the disease will cause individuals to 
becoming increasingly insulin deficient and develop dysfunctional glucose counter-regulation 
mechanisms similar to that seen in those with type 1 diabetes [12]. 
The reduced epinephrine response in patients with diabetes may decrease the initial autonomic 
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symptoms of hypoglycemia, resulting in ‘hypoglycemia unawareness’ [2, 11, 12]. As a result, the first 
signs of hypoglycemia may not occur until an individual is confused or has a reduced level of 
consciousness [33].  In addition, repeated episodes of hypoglycemia may cause the threshold for the 
epinephrine response to 'shift' to lower blood glucose concentrations [12], resulting in more frequent 
and severe episodes of hypoglycemia[12, 33]. From a practical point of view, recurrent episodes of 
hypoglycemia may also influence patients to avoid strict glucose control [33, 34].   This behavior may 
prevent patients from achieving the level of glycemic control necessary to decrease the risk of diabetic 
complications [33]. 
The 2009 COMPUS systematic review also explored the impact of SMBG on hypoglycemic 
episodes in patients with type 2 diabetes not using insulin[7, 8].  The risk of overall hypoglycemia was 
higher in patients performing SMBG compared to those who did not perform SMBG.  Pooling the 
results of 3 randomized controlled trials that reported the effect of SMBG (compared to no SMBG) 
resulted in a higher relative risk of overall hypoglycemia in patients performing SMBG (RR 1.99, 95% 
CI [1.37, 2.89]). There was no significant difference noted for rates of severe hypoglycemia between 
SMBG and control arms, but very few severe hypoglycemic events were reported in the included 
trials[7].  The increased risk of hypoglycemia in subjects performing SMBG was thought to be due to 
increased detection. The review concluded that there is unlikely to be a significant effect of SMBG on 
the relative risk of overall hypoglycemia in patients using oral hypoglycemics alone [7]. 
The 2012 Cochrane review of SMBG in patients with non-insulin treated type 2 diabetes was 
also unable to find good evidence that SMBG reduced hypoglycemic events.  In the four trials that 
reported hypoglycemia as an outcome, hypoglycemic episodes were reported more frequently in 
SMBG arms than in control arms.  The authors stated this to be an expected finding, as subjects 
performing SMBG are able to definitively confirm both symptomatic and asymptomatic episodes of 
hypoglycemia [8].  However, they also noted that as different studies use different definitions 
hypoglycemia, it is difficult to distinguish between the severities of the events that may have been 
detected by SMBG [8], and thus the benefits of increased detection (or consequences of non-detection) 
may be underestimated.  There appeared to be a benefit of SMBG in patients using insulin 
secretagogues, as detection of hypoglycemia with SMBG may reduce the progression of asymptomatic 
events [7, 39].  However, this was not a pre-specified outcome and was subjectively reported[7], 
providing only initial evidence about the degree of benefit in this patient population. 
Conventional wisdom suggests greater uptake of SMBG will decrease the incidence of 
hypoglycemia among patients with diabetes.  Although this theoretical association is widely accepted 
13 
by health care providers, surprisingly little evidence is available to confirm it.  In fact, the vast majority 
of high quality studies suggest SMBG increases the incidence of hypoglycemic episodes, presumably 
through increased detection of asymptomatic events [7, 8, 26-28].  At the same time, a favourable 
effect of SMBG on severe hypoglycemia has not been demonstrated (Table 1).  Most of the literature 
surrounding SMBG demonstrates improvements in glycemic control, with hypoglycemia reported as a 
secondary outcome.  The increased detection of hypoglycemia among patients practicing SMBG either 
represents the pathway by which serious hypoglycemic emergencies can be avoided, or it may just be 
drawing attention to nuisance levels that are not clinically dangerous.  Currently available data do not 
provide enough information to clarify the impact of SMBG on this issue.    
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Table 1:  Summary of key studies providing evidence for SMBG and hypoglycemia outcomes 
Author and 
Year 
Population Study aim/Intervention Key Findings 
Farmer et al, 
2007[26] 
Non insulin 
treated type 2 
diabetes 
To determine if self-monitoring (with or 
without additional instruction) more 
effective than usual care in improving 
glycemic control 
 
Primary outcome: HbA1c at 12 months 
 
Hypoglycemia not specified as outcome, 
but episodes of hypoglycemia reported 
each study visit and categorized according 
to severity 
One or more mild hypoglycemic events 
experienced by 14 subjects in control arm, 33 
participants in less-intensive SMBG arm, and 
43 subjects in more intensive SMBG arm 
(p<0.001).  One control group subject 
experienced an episode of moderate 
hypoglycemia.  
 
 
Increased reporting of hypoglycemia in the 
monitoring arms thought to be due to an 
increased awareness of hypoglycemia that 
could be confirmed using SMBG  
O’Kane et al, 
2008[28] 
Newly 
diagnosed type 2 
diabetes 
To determine if self-monitoring improved 
glycemic control and attitudes and 
satisfaction with treatment as compared 
with usual care 
 
Primary outcome: differences in HbA1c, 
psychological indices and incidence of 
hypoglycemia at 12 months 
Unable to detect a significant effect of SMBG 
on incidence of hypoglycemia 
 
SMBG arm: 18 subjects reported 33 episodes 
of hypoglycemia 
 
Control arm: 13 subjects reported 36 episodes 
of hypoglycemia 
 
Severity of episodes not defined and the 
difference between groups found to be non-
significant at all time points  
Barnett et al, 
2008[39] 
Type 2 diabetes 
receiving a 
sulfonylurea-
based regimen 
To determine contribution of SMBG to 
diabetes management 
 
Primary outcome: HbA1c at 27 weeks 
 
Hypoglycemia not prespecified outcome, 
however subjects in SMBG group also 
received instruction in managing 
suspected or SMBG-confirmed 
hypoglycemia 
 
All subjects kept diary to record 
symptoms suggestive of hypoglycemia 
Significant reduction in symptomatic 
hypoglycemic events in SMBG arm. 
 
Total number of hypoglycemic events similar 
in both arms (51 events in the SMBG arm 
and 66 in the control arm), but number of 
symptomatic hypoglycemic events more than 
twofold less in SMBG arm (27 events versus 
64 events) [39] 
 
Guerci, et al 
2003[27] 
Type 2 diabetes 
poorly 
controlled on 
oral 
hypoglycemic 
therapy (i.e. 
HbA1c values 
between 7.5-
11%) 
To compare metabolic control in patients 
managed with standard care utilizing 
SMBG compared with standard care alone 
 
Primary outcome: change in HbA1c at 6 
months 
 
Frequency of hypoglycemia (symptomatic 
and asymptomatic) reported as secondary 
outcome 
Hypoglycemic episodes occurred in 78 
subjects: 53 (10.4%) occurred in SMBG 
group and 25 (5.2%) in standard care group 
 
Difference between groups significant 
(p=0.003) and due to increased detection of 
asymptomatic hypoglycemia in the SMBG 
group  
 
No serious events of hypoglycemia in either 
group reported during study [27] 
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Hospitalizations and health care utilization 
The increased rate of hypoglycemic events associated with SMBG is undoubtedly due to 
increased detection [7, 8].  Individuals who self-monitor are able to confirm suspected symptoms of 
hypoglycemia and self-treat, or be able to detect episodes of asymptomatic hypoglycemia, especially in 
those on sulfonylureas [39] or insulin.  On this basis, it would seem reasonable that individuals 
employing SMBG may require fewer emergency department visits and/or subsequent hospitalizations 
for hypoglycemia.  There has been substantial research examining the relationship between variables 
such as age, disease duration, and treatment modalities on hospitalization rates for hypoglycemia [29, 
31, 32, 34, 40]. However, to our knowledge, SMBG has not been significantly explored as a factor for 
its potential to prevent hospitalizations for hypoglycemia. 
In order to determine risk factors for hospital admission due to hypoglycemia in patients with 
type 2 diabetes on oral hypoglycemics, Quilliam performed a nested case-control study in a cohort of 
type 2 diabetic subjects who received at least one oral hypoglycemic agent [40]. A total of 1,339 
patients with a first hospital admission for hypoglycemia were identified as cases and matched to 
controls based on cohort entry date.  Overall, cases had more comorbidities and cardiovascular disease 
than controls, and the presence of macrovascular and microvascular complications of diabetes were 
independent predictors of hospital admission.  Previous emergency department and outpatient visits for 
hypoglycemia were also strong predictors of hospital admission for hypoglycemia.  Metformin was 
associated with a reduced risk of hospital admission, while sulfonylureas and insulin use were 
associated with increased risk.  Age was not a predictor of admission in the adjusted model.  The use of 
blood glucose monitoring supplies was associated with a slight reduction in risk for admission 
(adjusted OR 0.83; 95% CI [0.71,0.96]), however this was non-significant in the unadjusted model (OR 
1.02; 95%CI [0.9,1.15])[40].  A related case-control study by the same authors examined factors 
associated with Emergency Department (ED) visits for hypoglycemia in patients with type 2 diabetes 
using oral hypoglycemics.  Factors increasing the risk of ED admission were similar to that of hospital 
admission, although female sex and lower age were associated with an increased risk.  Use of blood 
glucose strips was low in both cases and controls (25.6% of cases and 21.4% of controls), and model 
results for SMBG utilization was not reported [31]. 
The 2011 Survey on Living with Chronic Diseases in Canada-Diabetes Component (SLCDC-
DM) surveyed 2,862 respondents identified as having type 2 diabetes in order to determine the 
prevalence, frequency, and correlates of SMBG in this patient population [41].  In addition to obtaining 
self-reported testing prevalence and frequency information for SMBG, respondents were also asked if 
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they had visited an emergency department for hypoglycemia within the last year.  The prevalence of 
SMBG did not differ between respondents on insulin alone, insulin with oral hypoglycemics, or oral 
hypoglycemics alone. SMBG was performed more frequently by those who reported a hypoglycemia-
related emergency department visit than those who did not; the mean number of tests per week for 
respondents reporting a hypoglycemia-related emergency department visit within the last year was 
18.4, compared to 10.2 tests per week in respondents who denied having a hypoglycemia-related 
emergency department visit (p<0.05)[41]. More frequent SMBG did not decrease the risk of 
hypoglycemia-related emergency department visits in this survey; however data was self-reported, 
vulnerable to selection bias, and was cross-sectional and therefore was likely unreliable to truly explore 
the relationship between SMBG and hospital or emergency department visits for hypoglycemia. 
Although not designed to examine the association between test strip utilization and 
hypoglycemia hospitalizations, Booth et al. conducted a population-based time series analysis to 
determine trends in hospital admissions and emergency department visits for hypo- and hyperglycemia 
in Ontario from 1994-1998 [42].  After adjusting for fiscal year, age, sex, and various socioeconomic 
factors, they noted a marked 76% decline in the number of hospital admissions for hypoglycemia over 
the 5-year period (-18.7 per 100,000/year).  Over the same time period, ED visits for hypo- and 
hyperglycemia (combined) also declined (-307.8 per 100,000/year).  The authors postulated that as both 
indices declined simultaneously, the results suggest a true decline in the number of episodes of 
hypoglycemia [42], rather than a change in admitting thresholds or practices over the time period and 
may have been the result of improved diabetes care and management.   
 A second Ontario-based study provided preliminary insight into the relationship between test 
strip utilization and ED visits for hypoglycemia [43].  In 2017, Gomes et al. conducted a cross-
sectional time series among Ontario drug plan beneficiaries to examine the impact of test strip quantity 
restriction on ED visits for hypoglycemia.  Despite a 20% reduction in test strip utilization after the 
imposition of test strip reimbursement limits, no significant impact was observed on the rate of ED 
visits for hypoglycemia [43].  This effect was similar when patients were stratified according to mode 
of diabetes therapy and in a subgroup of heavy test strip users.  
These types of analyses have not been formally carried out in Saskatchewan.  Anecdotal and 
internal data suggests that hospitalizations for hypoglycemia in Saskatchewan may also declined over 
the last two decades. Given the dramatic increase in test strip usage over the same time period, it is 
possible that the two factors are related. SMBG has been associated with increased detection of 
hypoglycemia in clinical trials, which could theoretically lead to a decrease in serious events through 
17 
early detection.  However, current evidence suggests SMBG may have no impact on the risk of 
hypoglycemia hospitalization in lower-risk patients.   
As the majority of test strip use in Saskatchewan is in patients at low risk of hypoglycemia[10], 
it appears as though substantial resources are being invested with little potential for benefit.  Therefore, 
the purpose of this project was to determine the relationship between blood glucose test strip use and 
rates of hypoglycemia-related healthcare utilization in Saskatchewan, and to explore the degree to 
which blood glucose test strip use affects the risk of being hospitalized for hypoglycemia. 
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Objectives 
1. To determine if utilization of blood glucose test strips at the provincial level result in lower rates of 
hospitalizations for hypoglycemia. 
   
2. To determine if the individual risk of hospitalization for hypoglycemia is lower among patients who 
use blood glucose test strips compared to those who do not. 
 
Hypothesis 
• A crude inverse association between test strip use rate and hospitalization rates will be observed 
when no adjustment is made for confounding factors. 
• The use of blood glucose test strips does not reduce the risk for a hypoglycemia hospitalization 
except for those taking high doses of insulin.   
 
Chapter 3: Methods and Procedures 
Data source 
The Saskatchewan Ministry of Health maintains several databases containing health services 
information including a population registry, vital statistics information, hospital discharge abstracts, 
physician claims, and prescription drug claims.  Each Saskatchewan resident is assigned a unique 
patient identifier (i.e. Health Services Number, or HSN) that remains unchanged over time.  The HSN 
is included in all health service records allowing information in each database to be electronically 
linked.  The population registry contains demographic information, dates of coverage (i.e. entry and 
exit dates) and location of residence. The population registry includes approximately 99% of the 
population; people with federally funded health care (i.e. Canadian Forces, Royal Canadian Mounted 
Police, and inmates of federal penitentiaries) are excluded from the registry.  The registry is verified by 
routine computer and manual checks to maintain its accuracy and currency [44, 45].  Vital statistics 
captures all births, marriages, deaths, and name changes that occur in the province of Saskatchewan.   
The adjudicated prescription drug claim database covers approximately 90% of the population with the 
exception of those who have drug coverage under a federal program (i.e., registered First Nations, 
federal inmates, Canadian military officers and veterans, and Royal Canadian Mounted Police). The 
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prescription database records all outpatient dispensations for medications from an extensive formulary 
and some drugs receiving prior authorization. Dispensations for drugs available without a prescription 
(i.e. over-the-counter), professional samples, and hospital inpatient drug use are generally not captured.  
For each medication dispensed, the Prescription Drug Database captures the generic and brand name, 
Drug Identification Number (DIN), drug class (by American Hospital Formulary System) date of 
dispensation, strength, dosage form, quantity, and prescriber and cost information of each dispensed 
drug [46].  Dispensations for drugs not approved for coverage have been captured in a separate, non-
adjudicated claims database since 2006.  There is no information on clinical indication, dosage 
regimen, or adherence available in the prescription claims database [44].     
The medical services database includes all fee-for-service physician claims in Saskatchewan.  
Most medically necessary services are considered a benefit and all members of the eligible population 
are covered.  The majority of physicians in Saskatchewan are reimbursed by the fee-for-service model; 
however, physicians paid by other means (e.g. salary) are encouraged to submit shadow claims for 
services performed [44, 47].  Each claim in the medical services database contains patient and provider 
identifiers, provider specialty, International Classification of Diseases (ICD) codes for primary 
diagnosis (coded to 3 digits), fee codes for procedures, and the location of service (e.g. physician 
office, hospital inpatient, hospital outpatient, emergency room, and home visit) [44, 48]. Submitted 
claims are cross-checked to determine validity and eligibility within the population registry [44].  
The hospital discharge database contains a unique record for every discharge, transfer, or death 
occurring in all hospitals in the province.  Each record includes demographic information (age, gender, 
and HSN) and information related to their hospital stay, such as admission and discharge date, main 
diagnosis, secondary diagnoses (up to 25), an accident code, length of stay, hospital identification, and 
their disposition (i.e. home, transfer to another hospital or term care facility, or death) [46, 49].  
Diagnoses coding is done at the local level by health records administrators according to ICD standards 
and is recorded up to 6 digits [46, 49].  Since 2001, Saskatchewan has reported diagnosis according to 
the International Classification of Diseases (Tenth Revision, Canada) (ICD-10-CA) classification; prior 
to 2001, the International Classification of Diseases (Ninth Revision)(ICD-9) classification was used 
[45].  Limited routine validation of coding accuracy is also performed centrally. Data from the hospital 
discharge database is supplied to the Canadian Institute for Health Information (CIHI) and is collated in 
the Discharge Abstract Database (DAD).  CIHI collects and analyzes health and health care 
information in Canada for statistical purposes, rather than for billing and remuneration [49].  The DAD 
includes demographic, clinical, and administrative data on inpatient hospital discharges that is supplied 
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to CIHI from hospitals across Canada.  All hospitals, with the exception of those in the province of 
Quebec, are required to submit discharge information to CIHI [49]. CIHI conducts annual data re-
abstraction studies to assess the ongoing quality of the coding and abstracting of clinical and non-
clinical data contained within the DAD [49].  The most currently available data quality re-abstraction 
study evaluated 2009-2010 data, at both the national and provincial level.  For the province of 
Saskatchewan, the authors reported that 86% of ICD-10-CA coded significant diagnoses reported in the 
DAD were confirmed in chart review, 77% of significant diagnoses recorded in chart review were 
present in the DAD, and an ICD-10-CA coding consistency of 86% [49]. Validation studies of the 
Saskatchewan Health Databases have been done for a wide range of medical conditions [44, 45] and its 
accuracy for use in research has been demonstrated in numerous studies [50-53]. 
Study data was accessed in the Saskatchewan Health Quality Council (HQC) via a secure 
virtual private network connection to a data warehouse located in eHealth Saskatchewan’s servers. 
HQC’s access to and use of these data are regulated by a data sharing agreement (DSA) between the 
Ministry of Health and HQC.  An exemption from ethics approval for research was obtained from the 
University of Saskatchewan Biomedical Research Ethics Board (BIO 16:35), February 22, 2016. 
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Objective 1: To determine if utilization of blood glucose test strips at the provincial 
level result in lower rates of hospitalizations for hypoglycemia. 
  
• Sub-objective 1.a--Conduct a time-series analysis to determine if an association exists 
between population-level usage of blood glucose test strips and hospitalizations for 
hypoglycemia  
 
 
Sub-objective 1.a – Conduct a time-series analysis to determine if an association exists between 
population-level usage of blood glucose test strips and hospitalizations for hypoglycemia  
 
 
Study Design 
A retrospective, observational study design was used.  Time series analyses were constructed 
for a) the number of hospitalizations for hypoglycemia and; b) the number of glucose test strips 
dispensed annually between January 1st, 1996 and December 31, 2014.  Only beneficiaries of the 
Saskatchewan drug plan were included as drug and strip usage data for individuals with federal drug 
coverage was not captured in the prescription drug database (i.e., adjudicated claims database). 
 
Identification of hypoglycemia cases 
 
 In each calendar year, starting from 1996, the total number of cases of hypoglycemia were 
measured using the following endpoints:  a) Number of individuals with at least one hospital admission 
for hypoglycemia; b) Number of hospital admissions for hypoglycemia; c) number of individuals with 
at least one physician service claim for hypoglycemia; and d) number of physician service claims for 
hypoglycemia. 
Hospitalization for hypoglycemia was identified using ICD-9 and ICD-10-CA codes indicating 
a diagnosis of hypoglycemia in the DAD in any diagnostic field (Table 2).  To avoid capture of events 
occurring during the hospital stay, all hypoglycemic events designated as ‘Type 2’ diagnoses (i.e. post-
admit comorbidities) were excluded [54, 55].  Ginde et al validated an ICD-9 based algorithm to 
accurately identify hospitalizations for hypoglycemia. The algorithm (adapted in Table 2) was found to 
have an overall positive predictive value of 89% (95% CI 86-92) for identifying hospitalizations for 
hypoglycemia [56].  Although we were not aware of a similar algorithm using ICD-10-CA codes, ICD-
10-CA codes were examined to ensure correspondence with ICD-9 diagnosis codes.   Neonatal 
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hypoglycemic events (i.e. ICD-9 codes 775.0 and 776.0) were excluded as they were not clinically 
relevant to the analysis.  
 
Table 2: Diagnostic codes (ICD-9 and ICD-10-CA) used to identify hypoglycemia hospitalizations 
[42, 56, 57] 
ICD Classification Code Description 
ICD-9 251.0 Hypoglycemic coma 
ICD-9 251.1 Other specified hypoglycemia 
ICD-9 251.2 Hypoglycemia, unspecified 
ICD-9 270.3 Leucine-induced hypoglycemia 
ICD-9 250.8 (in absence of other 
contributing diagnoses:  
259.8  
272.7  
681.xx, 682.xx, 686.9x  
707.1-707.9  
709.3  
730.0-730.2, 731.8  
Diabetes with other specified manifestations, 
excluding:  
Secondary diabetic glycogenosis 
Diabetic lipidosis 
Cellulitis 
Ulcers of the lower extremity 
Oppenheim-Urbach syndrome 
Osteomyelitis 
ICD-10-CA E10.63 Type 1 diabetes mellitus with hypoglycemia 
ICD-10-CA E11.63 Type 2 diabetes mellitus with hypoglycemia 
ICD-10-CA E13.63 Other specified diabetes mellitus with hypoglycemia 
ICD-10-CA E14.63 Unspecified diabetes mellitus with hypoglycemia 
ICD-10-CA E15.0 Non-diabetic hypoglycemia coma 
ICD-10-CA E16.0 Drug induced hypoglycemia 
ICD-10-CA E16.1 Other hypoglycemia 
ICD-10-CA E16.2 Hypoglycemia unspecified 
 
Physician visits for hypoglycemia were recorded from the medical services database and 
identified by the ICD-9 code 251 in the diagnosis field.  The medical services database captures a 
single, three-digit ICD-9 diagnosis code collected for remuneration purposes and may not be 
completely representative of the reason for the visit. In addition, the three-digit code describes the 
diagnosis in broad terms only; no further detail regarding specifics of the disease or condition can be 
obtained. To our knowledge, use of the physician claims database to identify hypoglycemia has not 
been validated; however, it was felt to be a measure that should be recorded to provide a 
comprehensive picture of health services claims over time.  
 
 
Additional secondary endpoints 
Additional endpoints were also tracked during the observation period to provide context for the 
observed trends in hypoglycemia events.  All-cause hospitalizations consisted of the annual number of 
hospitalizations resulting in at least one night’s stay. In addition, hypoglycemic medication utilization 
consisted of the annual number of individuals receiving at least one dispensation for a hypoglycemic 
medication.  Trends over time were examined independently for each endpoint. 
23 
 
 
 
Emergency Department (ED) visits for hypoglycemia 
The annual rate of hospitalization for hypoglycemia may be influenced by changes in admitting 
thresholds in provincial emergency departments (ED).  For example, decreases in hypoglycemia 
hospitalizations could result if a higher percentage of these cases were managed and released directly 
from the ED (i.e., without hospital admission).  To estimate the impact of ED activities on 
hypoglycemia-hospitalization trends, ED databases from the two largest urban centres in Saskatchewan 
were accessed (Saskatoon and Regina).  Visits for hypoglycemia were identified from ICD-10-CA 
codes (Table 2) indicating hypoglycemia as the main reason for the ED visit.  The annual number of 
ED visits for hypoglycemia were described along with the percentage of individuals who were 
subsequently hospitalized.  
 
Test Strip Utilization 
Blood glucose test strip use was measured annually according to the following endpoints: a) the 
total number of test strips dispensed; b) total number of individuals receiving at least one strip; and c) 
total number of test strip dispensations. Test strip dispensations were identified by their DIN and 
captured from the adjudicated prescription claims database.  Test strip brand names (and associated 
DINs) identified as a benefit under the Saskatchewan Drug Plan Formulary are given in Table 3. This 
analysis was conducted in the same manner as the previous SDUORT analysis of test strip utilization, 
with additional drug data that had become available [10]. 
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Table 3:  Blood glucose test strip products listed as benefits under the Saskatchewan Drug Plan 
(by name and DIN) from 1996-2014 [22]  
 
DIN Test strip name DIN Test strip name 
00950599 ACCU-CHEK 97799597 FREESTYLE LITE 
00950926 ACCU-CHEK ADVANTAGE 97799596 FREESTYLE LITE 
00950949 ACCU-CHEK AVIVA 00950894 FREESTYLE PRECISION STRIP 
00950900 ACCU-CHEK COMPACT 97799373 GE200 BLOOD GLUCOSE STRIP 
00951190 ACCU-CHEK INFORM II 97799372 GE200 BLOOD GLUCOSE STRIP 
97799497 ACCU-CHEK MOBILE 00950378 GLUCOFILM 
00950432 ACCUTREND 00950878 GLUCOMETER DEX 
00950661 ADVANTAGE 00950408 GLUCOSTIX 
00950883 ADVANTAGE COMFORT 00950956 ITEST 
00950878 ASCENSIA AUTODISK 97799594 LIFE BRAND 
00950960 ASCENSIA BREEZE 2 97799595 LIFE BRAND PORTABLE 
00950924 ASCENSIA CONTOUR 00951177 MEDISURE 
00950878 ASCENSIA DEX 97799458 MYGLUCOHEALTH TEST STRIPS 
00950924 ASCENSIA MICROFILL 97799583 NOVAMAX 
00950911 BD LATITUDE STRIP 00950889 NOVO-GLUCOSE 
00950911 BD TEST 97799582 ON-CALL PLUS 
97799465 BGSTAR 00950459 ONE TOUCH 
97799478 BIONIME RIGHTEST GS100 00950893 ONE TOUCH ULTRA 
97799394 BRAVO BLOOD GLUCOSE TEST 00950459 ONE TOUCH ULTRA 
00950960 BREEZE 2 97799476 ONETOUCH VERIO 
00950068 CHEMSTRIP BG 00950912 PRECISION EASY 
00950924 CONTOUR 00950300 PRECISION PLUS 
97799459 CONTOUR NEXT 00950894 PRECISION XTRA 
97799460 CONTOUR NEXT 00950831 PRESTIGE 
00950572 ELITE 97799451 RAPID RESPONSE 
00950505 ENCORE 00950948 SIDEKICK 
00950122 EXACTECH 00950902 SOF-TACT 
97799564 EZ HEALTH ORACLE 00950734 SURESTEP 
00950882 FASTTAKE 97799355 SURETEST 
00950907 FREESTYLE 97799532 TRUETEST 
  00950957 TRUETRACK SMART SYSTEM 
 
 
  
25 
 
Data Analysis 
 
Test strip dispensations and hypoglycemia endpoints were graphed annually to show the trend 
of use over the study period.  In order to account for changes in population demographics over time, all 
endpoints were standardized by age group (5-year intervals) and sex [58, 59].  The 2005 population of 
active beneficiaries was used as the reference population to directly standardize hospitalizations and 
test strip use per calendar year. The crude number of test strips (or hypoglycemic events) in each age-
sex group was converted to a rate and multiplied by the corresponding reference/standard population in 
that age-sex group.  The sum of the standardized endpoint across all age-sex groups for a given year 
gave the age-sex standardized measure of test strip use and hypoglycemic events [59].  
Unadjusted changes in each endpoint were estimated over the study period using least squares 
regression models. Graphs of each endpoint versus time (i.e. calendar year) were constructed to 
visualize initial trends and relationships between variables. Quantile-quantile plots of standardized 
residuals were constructed to assess the distribution of residuals.  Independence of errors was assessed 
using the Durbin-Watson test [60].  The coefficient of determination (i.e. adjusted R2 statistic) was 
reported for each model to estimate the degree to which the model fit the observed data [60, 61].  The 
least squares regression model for each outcome was given by the equation Y= β0 + β1 x + ε, with the 
equation variables given in Table 4. 
 
Table 4:  Variables included in least squares regression model 
Variable Definition 
Y Outcome  (i.e. age and sex standardized number of 
hypoglycemia events and age-sex standardized test strip 
use) 
β0 Regression Y-intercept 
β1 Coefficient representing impact of time (x)(Regression 
slope) 
x Time period represented by number of years since 
beginning of observation period (0, 1, 2….x) 
ε Error term 
 
 Generalized estimating equations (GEE) fit within a generalized linear model (GLM) 
framework were used to test the association between test strip use and hypoglycemic events at the 
population level.  As hospitalizations for hypoglycemia and test strip dispensations were measured 
repeatedly in the study population, it was unlikely these would represent independent endpoints. 
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Therefore, GEEs were used to model the trend of hypoglycemia admissions over time, while 
accounting for potential autocorrelation within the data [62-64].  
Individuals were stratified by age group, sex, and year.  Age group categories were by 5-year 
intervals, except for the youngest and oldest (i.e. less than 1 year and greater than 95 years). 
Independent variables in the analysis were test strip usage and the total number of hospitalizations (all-
cause) for each strata (Table 5). The population of each stratum was included as a constant in the 
model. The dependent variable (i.e. total number of hospitalizations for hypoglycemia) was obtained 
for each age/sex/year strata. The model was used to determine if test strip use was an independent 
predictor of total annual hospitalizations for hypoglycemia, while controlling for year, age, sex and 
overall healthcare utilization [62]. 
In order to determine the distribution of the dependent variable, the intercept-only model was 
tested with both a Poisson and negative binomial distribution.  The ratio of variance to degrees of 
freedom was used to establish which distribution best represented that of the dependent variable [63] .  
Both autoregressive and exchangeable correlation structures were postulated to be a reasonable 
estimate of the correlation that may exist within the data.  The correlation structure that resulted in 
lower values of the quasi-likelihood information criteria (QIC) was chosen for model construction [63]. 
 
 
 
Table 5:  Variables included in the GEE model 
Variable Definition 
Y Outcome (total number of hospitalizations for hypoglycemia in 
the strata) 
x1 Year  
x2 Test strip utilization in each stratum 
x3 All-cause hospitalization in each stratum 
k Constant (natural logarithm of the population in each stratum) 
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Objective 2: To determine if the individual risk of hospitalization for hypoglycemia is lower 
among patients who use blood glucose test strips compared to those who do not.  
 
Methods 
A nested case control study was used to identify the impact of blood glucose test strip use on 
the risk for hypoglycemia requiring hospitalization.  Individuals were entered in the cohort if they 
satisfied all the following criteria:  a) were a beneficiary of the Saskatchewan drug plan; b) met the 
Canadian Chronic Disease Surveillance System (CCDSS) case definition for diabetes after January 1st 
1996; and c) were at least 20 years of age at cohort entry.  The CCDSS case definition was met if 
individuals received two outpatient physician claims for diabetes within 730 days or one hospitalization 
indicating a diagnosis of diabetes [65] [Table 6].  For those meeting the case definition through 
outpatient physician claims, the cohort entry date corresponded to the date of the second claim.  For 
those hospitalized with diabetes, the cohort entry date was the discharge date.   
 
Table 6: Diagnostic codes (ICD-9 and ICD-10-CA) used to identify diabetes cases 
ICD Classification Code Description 
ICD-9 250.xx Diabetes mellitus 
ICD-10-CA E10.xx Type 1 diabetes mellitus 
ICD-10-CA E11.xx Type 2 diabetes mellitus 
ICD-10-CA E12.xx Malnutrition-related diabetes 
mellitus 
ICD-10-CA E13.xx Other specified diabetes 
mellitus 
ICD-10-CA E14.xx Unspecified diabetes mellitus 
 
According to the CCDSS definition, women with gestational diabetes mellitus were excluded 
from the analysis.  As drug usage data could not be obtained for persons under federal coverage 
programs prior to 2006, individuals with federal drug coverage were not included in the analysis.  In 
addition, those with less than 1 year of continuous beneficiary status prior to their cohort entry date 
were excluded.  All subjects were followed from the cohort entry date until the earliest occurrence of 
death, termination of provincial health benefits, or the end of the study period (December 31, 2014).     
The CCDSS definition of diabetes has been validated in individuals ≥ 20 years of age [66].  
Although it is not able to differentiate between type 1 and type 2 diabetes, it was found to have a 
sensitivity of over 95% upon its first validation in Manitoba using the provincial diabetes education 
database [47, 66]. It has been further validated using various ‘gold standards’ in different jurisdictions 
across the country [66].  In Saskatchewan, the sensitivity of the case definition has been estimated at 
28 
92% [47].  The inclusion of hypoglycemic agents in the case definition does not appear to improve its 
sensitivity or specificity [47]. 
 
Identification of cases and controls 
Cases were defined by the first occurrence of a hospital admission for hypoglycemia during the 
follow-up period (i.e., January 1st, 1996 to December 31, 2014).  Hospitalizations for hypoglycemia 
were identified from DAD records listing ICD-9 or ICD-10-CA codes indicating a diagnosis of 
hypoglycemia [Table 1] in any diagnosis field.  To avoid capture of hypoglycemic events occurring in 
hospital, all hypoglycemic events designated as ‘Type 2’ diagnoses (i.e. post-admit comorbidities) were 
excluded [54, 55]. Cases were assigned an index date corresponding to the admission date for their first 
hospitalized hypoglycemic event [31, 40]. To ensure all patient exposures could be evaluated for six 
months preceding the event, patients experiencing hypoglycemic events within 180 days of cohort 
entry were excluded for the primary analysis.  However, they were re-introduced in sensitivity analyses 
to determine if their presence affected final estimates.  
Controls were selected using incidence density sampling [67].  As incidence density sampling 
estimates the entire at-risk experience of all those in the risk set, this approach is considered the most 
efficient and least biased sampling design for case-control studies [68]. For each case, four controls 
[69]  were randomly selected from the study cohort and assigned an index date that corresponded to the 
date of admission for their matched case.  Controls were matched according to their cohort entry date 
(year), by age category at cohort entry, and sex. A control for one case may have been selected as a 
control for another case occurring at a later date, providing they remained in the study cohort and 
therefore continued to be at risk of becoming a case.   Accordingly, controls may have also become 
cases at a later date [68, 70, 71].  Matching by age at cohort entry in 5-year age categories resulted in 
multiple cases that failed to match with a single control; thus, matching criteria for age was 
subsequently increased to 10-year intervals to allow for inclusion of all cases.     
 
Identification of Variables / Confounders 
 
The primary independent variable was the use of blood glucose test strips in the 180 days 
preceding the index date.  Test strip use was identified from the Saskatchewan Drug Plan database 
using their DIN [Table 3].  Cases and controls were categorized as test strip ‘users’ or ‘non-users’ 
based on the presence (i.e. user) or absence (i.e. non-user) of test strip dispensations in the 180-day 
period prior to the index date.  In sensitivity analyses, total number of test strips ‘on-hand’ was 
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categorized into an ordinal variable representing intensity of test strip use. 
Numerous possible confounders were identified either on the cohort entry date or during the 
exposure period.  Covariates were identified within the following categories: patient factors, 
treatment/drug factors, disease factors, and health care utilization and system factors.  Treatment/drug 
factors were identified by dispensations captured from the Prescription Claims database.  Disease 
factors were identified using ICD-9 and ICD-10-CA codes recorded in the Medical Services database 
and Discharge Abstract database.  Health system and healthcare utilization factors were identified using 
administrative variables obtained from the Medical Services database and DAD.  Covariates are 
described in detail in Table 7.    
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Table 7:  Variables included in conditional logistic regression analysis [31, 32, 34, 40, 72, 73] 
 
Covariate 
Category 
Covariate Covariate Definition Variable Name Variable Coding 
Primary 
Dependent 
Variable 
Outcome Hospitalization for 
hypoglycemia 
CACO 0=Control 
1=Case 
Primary 
Independent 
Variable 
Test Strip Use Dispensation of test strips in 
180 days prior to index date 
STRIP_USER 0=No 
1= Yes 
Patient Factors Location of 
residence 
Subject residence (rural or 
urban) according to postal code 
at index date  
URB_RUR 0= Urban 
1= Rural 
Treatment 
Factors 
Mode of diabetes 
therapy  
Category of diabetes treatment 
according to risk of 
hypoglycemia (Table 8) in 180 
days prior to index date 
DIAB_TX 0= No drugs 
1= Low risk oral 
hypoglycemic 
2= High risk oral 
hypoglycemic 
3= Insulin 
Disease Factors Comorbidity Score Charlson score[72] in 1 year 
period prior to index date 
CHARL_CAT 0=Charlson score 0 
1=Charlson score 1-4 
2=Charlson score 5 or 
more 
Previous outpatient 
visits for 
hypoglycemia  
Medical services claim 
indicating outpatient visit for 
hypoglycemia (i.e. ICD-9 code 
251) in 180 days prior to index 
date 
MSB_HYPO 0= No 
1=Yes 
Healthcare 
utilization and 
system factors 
Specialty Physician 
Care 
Medical services claim 
indicating specialist visit for 
treatment of diabetes in 180 
days prior to index date 
SPEC_DIAB_VISIT 0= No 
1=Yes 
Outpatient health 
care utilization 
Total number of outpatient 
visits occurring in 180 days 
prior to index date 
OUTPT_VISITS 0= 0-3 outpatient visits 
1=4-6 outpatient visit 
2=7-10outpatient visits 
3= ≥ 11 outpatient visits 
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Table 8: Classification of patients according to mode of diabetes therapy [10, 22]  
 
Treatment Category Definition Category specific medications available 
as a benefit under the Saskatchewan 
Drug Plan 
Insulin  At least one dispensation of insulin with or 
without an oral antihyperglycemic medication 
during the 180 days prior to the index date 
Rapid Acting: 
Insulin Lispro 
Insulin Aspart 
Insulin Glulisine 
 
Short Acting/Regular: 
Humulin R (Regular) 
Novolin ge Toronto 
Hypurin Regular 
 
Intermediate Acting: 
Humulin N 
Novolin ge NPH 
Hypurin NPH 
 
Long Acting: 
Insulin glargine 
Insulin determir 
 
Premixed: 
Humulin 30/70 
Novolin ge 30/70 
Novolin ge 40/60 
Novolin ge 50/50 
High risk oral 
hypoglycemic 
medication 
At least one dispensation for an oral agent with 
a high potential to cause hypoglycaemia 
without claims for insulin during the 180 days 
prior to the index date 
Tolbutamide 
Chlorpropamide 
Glyburide 
Low risk oral 
hypoglycemic 
medication 
At least one dispensation for an oral agent with 
a lower potential to cause hypoglycaemia 
without claims for insulin or high risk oral 
agent during the180 days prior to the index date 
Gliclazide 
Nateglitinide 
Repaglitinide 
Metformin 
Acarbose 
Rosiglitazone 
Pioglitazone 
Sitagliptin 
Saxaglitpin 
Linagliptin 
Rosiglitazone/Metformin 
Sitagliptin/Metformin 
No hypoglycemic 
medications received 
No claims for diabetes medications in the 180 
days prior to index date 
N/A 
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Analysis 
 
A conditional logistic regression model was developed to test if test strip use (the 
primary independent variable of interest) was independently associated with risk of 
hospitalizations for hypoglycemia.  Variables that were considered for inclusion in the model 
are given in Table 7.  The distributions of all independent variables were examined.  For 
categorical variables, contingency tables of the outcome against the levels of categorical 
variable were constructed.  Covariates were examined to determine if multicollinearity existed 
between independent variables and test strip use.  Potential collinear relationships were 
identified by pairwise correlation coefficients greater than 0.8 or Variance Inflation Factors 
(VIF) greater than five [74]. 
The conditional logistic regression model was constructed utilizing a theoretical-based 
approach.  Sets of covariates (Table 7) were added to the model sequentially to determine the 
effect of clinically related variables on the relationship between the primary independent 
variable and outcome.  In order to maximize control for confounding, a model containing all 
covariates in Table 7 was constructed.  
The covariates in the main effects model were then assessed for any clinically relevant 
interactions with the primary outcome variable. Clinically relevant interactions identified a 
priori that were tested included those between strip use and mode of diabetes therapy, strip use 
and comorbidity score, and strip use and previous outpatient visits for hypoglycemia.  
Statistically significant interactions were added to main effects models and evaluated using the 
Akaike Information Criterion (AIC) [75]  and Bayesian Information Criterion (BIC) [76] to 
identify best candidate models that fit the data well, while including clinically relevant 
variables. The unadjusted and adjusted odds ratios (along with 95% confidence intervals and 
corresponding p-values) for test strip use and other predictors of hospitalizations were reported.  
Sensitivity analyses were conducted with exposures being characterized in the 90-day 
period prior to the index date (i.e., versus 180 days) and with the inclusion of subjects with 
events occurring within the first 180 days of cohort entry that had previously been excluded 
from the analysis.  Additional sensitivity analyses that were conducted also included 
categorization of strip use to represent levels of use (i.e. none, lowest users, intermediate users, 
and highest users) [10], and according to drug use (i.e. therapeutic class of hypoglycemic).  A 
subgroup analysis in insulin users was also conducted, with insulin use stratified by average 
daily consumption (DACON) [77] of insulin. In the insulin-user subgroup, an interaction 
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between test strip use and insulin dosage (by DACON quartile) was also examined to determine 
if the relationship between test strip use and hospitalizations for hypoglycemia differed 
according to the intensity of insulin therapy.   
 
All statistical analyses were conducted using SAS version 9.4.   
  
34 
Chapter 4: Results 
Hospital admissions for hypoglycemia 
Between January 1, 1996 and December 31, 2014, a total of 5,166 hospitalizations for 
hypoglycemia were recorded in Saskatchewan.  The average annual crude rate was 272 hypoglycemia 
admissions among 1,039,150 beneficiaries, or 26.2 hypoglycemia admissions per 100,000. 
On visual inspection, no consistent trend was evident in hypoglycemia hospitalizations between 
1996 and 2014 (Figure 1).  The lowest number of hospitalizations for hypoglycemia occurred in 2001 
(158 hospitalizations among 147 individuals) and the highest number was recorded in 2007 (387 
hospitalizations among 346 individuals - Figures 1a and 1b).  Linear regression analysis was not 
applied to the entire study period due to non-linear trends in the endpoint over the study period. A 
similar trend resulted when the outcome was changed to the number of individuals with at least one 
hospital admission (Figure 1b).  Quantile-Quantile plots of residuals indicated that distribution of errors 
were approximately normal for hypoglycemia and hospitalization endpoints, but not for test strip 
endpoints. For all endpoints, the Durbin-Watson test indicated that positive autocorrelation was present 
in all models. 
Figure 1a and 1b:  Total number of hospitalizations for hypoglycemia (left) and total individuals 
with ≥1 hospitalization for hypoglycemia in Saskatchewan (right) from 1996-2014 
 
 
 
Additional investigations were undertaken to understand the descriptive results (including the 
poor model fit).  First, a review of drug policy, provincial drug availabilities, and coding practices did 
not reveal any obvious factors that might have explained the apparent increase in hospitalizations 
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between 2005 and 2006.  Second, the analysis was reproduced after restricting the cases of 
hypoglycemia to those specified as type 1 or type M (for most responsible) as well as restricting to 
those diagnoses occurring in the first two diagnostic positions.  All of these sensitivity analyses 
produced results consistent with the primary results.  The results were then stratified by time periods 
(i.e. 1996 to 2005, and 2006 to 2014) corresponding to visual inspection of the original time series 
(Figure 1).  After performing separate linear regression analyses on each time period, the change in the 
number of hypoglycemia hospitalizations from 1996 to 2005 was non-significant (p=0.20), while the 
number of hypoglycemia hospitalizations significantly decreased from 2006 to 2014 (annual decrease -
17.9; 95% CI [-24.47, -11.31], p<0.01, adj. R2 =0.83), which coincides with the qualitative trends 
described by Figure 1.  
All-cause hospitalizations were plotted to provide context relating to overall health care trends 
across the province (Figure 2).  The crude number of hospitalizations for any cause that resulted in at 
least one night’s stay increased from 591,391 hospitalizations in 1996 to 1,047,069 hospitalizations in 
2014, indicating an overall increasing trend in health care utilization over the study period (annual 
increase +13,879, 95% CI [10,638, 17,121], p<0.01,adj. R2 =0.82).  Of note, trends in all-cause 
hospitalizations were not consistent with those observed for hypoglycemia, especially in the latter part 
of the study period.      
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Figure 2:  Total number of hospitalizations for hypoglycemia and all-cause hospitalizations in 
Saskatchewan from 1996-2014 
 
 
Physician claims for hypoglycemia 
The frequency of physician claims for hypoglycemia during the observation period was much 
higher than that of hospitalizations. Between 1996 and 2014, a total of 41,322 claims for hypoglycemia 
were recorded.  Overall, physician claims for hypoglycemia declined over the study period (Figures 3a 
and 3b). The highest number of claims (2,504) was observed in 1998 representing 1,735 individuals. In 
2014, the crude number of physician claims for hypoglycemia was 1,856 resulting from 1,664 
individuals.  The decline was significant over the study period (annual decrease -46.7, 95% CI [-60.87, 
-32.60], p<0.01, adj. R2=0.73).  The number of individuals with at least one physician claim for 
hypoglycemia also exhibited a similar declining trend over the study period (annual decrease -38.8, 
95% CI [-48.83, -28.75], p<0.01, adj. R2= 0.78). 
Figure 3a and 3b:  Total number of physician claims for hypoglycemia (left) and total individuals 
with ≥1 physician claim for hypoglycemia (right) in Saskatchewan from 1996-2014 
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Blood glucose test strip utilization 
Blood glucose test strip utilization increased annually over the study period, both in terms of an 
increase in the number of test strips dispensed and the number of individuals receiving test strips.  In 
1996, 3.9 million strips were dispensed to 15,756 distinct users (59,493 dispensations).  In 2014, 18.2 
million test strips were dispensed to 42,051 distinct users (150,958 dispensations - Figures 4-6). The 
increases in all measures of test strip utilization were statistically significant over the study period.  The 
annual estimated increase in the total number of strips dispensed was +758,171 (95% CI [674,587, 
841,754], p<0.01, adj. R2 = 0.95), the annual increase in the total number of test strip dispensations was 
+4,418 (95% CI [3,419, 5,415], p<0.01, adj. R2 =0.83) and the annual increase in the number of 
individuals receiving at least one test strip was +1,216 (95% CI [1,009,1,424], p<0.01, adj. R2 = 0.89).   
 
Figure 4:  Total number of blood glucose test strips dispensed in Saskatchewan from 1996-2014 
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Figure 5:  Total blood glucose test strip dispensations in Saskatchewan from 1996-2014 
 
 
Figure 6:  Total number of individuals receiving at least one blood glucose test strip in 
Saskatchewan from 1996-2014 
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Hypoglycemic medication utilization 
The number of individuals receiving at least one hypoglycemic medication increased annually 
over the study period from 22,197 individuals in 1996 to 57,877 individuals in 2014 (Figure 7) (annual 
increase +1,565, 95% CI [1476,1653], p<0.01, adj. R2=0.98).   
 
Figure 7:  Total number of individuals receiving at least one hypoglycemic medication in 
Saskatchewan from 1996-2014 
 
 
ED visits for hypoglycemia 
Data for emergency department visits in Saskatchewan were only available from 2012 onwards 
(Table 9). Of all patients presenting to the ED for hypoglycemia during this period (n=608), only 15% 
(n=101) were admitted to hospital on the same day.  An additional 5% were admitted to hospital within 
7 days of an ED visit for hypoglycemia. 
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Table 9:  ED visits for hypoglycemia in SHR and RQHR from 2012 to 2014 
Year Total ED Visits Admitted to hospital 
on same day of ED visit 
Admitted to hospital 
within 7 days of ED 
visit 
2012 223 33 <6 
2013 191 39 10 
2014 194 29 12 
 
 Association between test-strip utilization and hospitalizations for hypoglycemia 
To obtain a reliable estimate of the relationship between hypoglycemia hospitalizations and 
blood glucose test strip usage, a GEE model was fit to account for autocorrelation within the time 
series.  When initially fit with a Poisson distribution, the resulting model possessed a ratio of variance 
to degrees of freedom of 6.30, indicating over-dispersion was present. When fit with a negative 
binomial distribution, the resulting model possessed a ratio of variance to degrees of freedom of 1.12, 
indicating a better fit to distribution of the dependent variable. The negative binomial distribution (and 
corresponding log link function) was therefore used for model construction [63].  Both the 
autoregressive and exchangeable correlation structure appeared to fit the data reasonably well, however 
the exchangeable correlation structure resulted in smaller values of the QIC and was chosen for model 
construction [63].  
After controlling for the number of all-cause hospitalizations and changes in population size, 
the total number of test strips dispensed was not associated with a significant change in the rate of 
hospitalizations for hypoglycemia (p=0.41) (Table 10). The test strip utilization endpoint in the model 
was also measured in terms of the total number of test strip dispensations.  This made little difference 
to the overall association between test strip use and hospitalizations for hypoglycemia. The average 
annual rate of change for hypoglycemia hospitalizations was estimated as +3% over the study period 
(multiplicative rate increase 1.03 [95% CI 1.01-1.05], p<0.01). 
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Table 10:  Hypoglycemia hospitalizations as a function of year, the total number of test strips 
dispensed (in millions), and all-cause hospitalizations (in millions) 
Parameter Estimate Empirical 
Standard 
Error 
95% Confidence 
Limits 
p-value 
Intercept -7.84 0.24 (-8.30, -7.38)  <0.01 
Year 0.03 0.01 (0.01, 0.05) <0.01 
Test strips dispensed 
(millions) 
0.18 0.22 (-0.25, 0.60) 0.41 
All-cause hospitalizations 
(millions) 
-5.80 7.11 (-19.74, 8.14)  0.41 
 
  
42 
 
Objective 2:  To determine if the risk of hospitalization for hypoglycemia is lower among patients 
who use blood glucose test strips compared to those who do not. 
Cohort Definition 
Between January 1, 1996 and December 31, 2014, a total of 118,502 beneficiaries of the 
Saskatchewan Drug plan met the CCDSS case definition for diabetes (Figure 8).  As the CCDSS case 
definition has not been validated in individuals younger than 20 years of age, those who were less than 
20 years of age at cohort entry were excluded. An additional 342 beneficiaries were excluded from the 
overall cohort due to incomplete coverage records, while 6,071 beneficiaries were excluded due to 
having less than 1 year of continuous coverage prior to cohort entry. The final cohort consisted of 
110,011 beneficiaries.  The mean age at cohort entry was 62.1 years (SD 15.1) and 54.6% of cohort 
members were male. 
Figure 8:  Construction of overall diabetes cohort 
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During a mean follow-up of 7.8 years, 2.6% of the diabetes cohort (2,827/110,011) was 
hospitalized for hypoglycemia.  Of these, 197 individuals were excluded because their hypoglycemic 
event took place within the first 180 days of cohort entry and as a consequence, their exposure period 
could not be fully characterized.  Thus, 2,630 cases were identified.  Compared to patients who did not 
experience hypoglycemia, cases were slightly older (mean age at index 72.8 years vs. 71.7 years), 
received more hypoglycemic medications (90.1% vs. 73.9%), had a higher comorbidity burden, and 
visited their physicians more often.    
Cohort members hospitalized for hypoglycemia (i.e., cases) were randomly matched to 4 
controls by sex, age category, and cohort entry date (+/- 1 year). Ultimately, 10,520 matched controls 
were selected to achieve a final study cohort of 13,150 individuals.   Descriptive characteristics of cases 
and controls are given in Table 11.  
Important differences were observed between cases and controls.  Over 80% of cases were 
dispensed insulin or high-risk oral hypoglycemic agents in the 180 days prior to index date, as 
compared to less than 50% of controls.  Similarly, 90% of cases received a dispensation for any 
diabetes medication in the exposure period compared to less than 75% of controls.   Cases also had 
more frequent outpatient physician claims, and higher comorbidity.  Outpatient claims for 
hypoglycemia were recorded in 12.7% of cases compared to less than 1% of controls.  Furthermore, 
approximately 25% of outpatient claims for hypoglycemia occurred within one day of a hospitalization 
for hypoglycemia.  As such, it was postulated that having a previous outpatient claim for hypoglycemia 
may be in the causal pathway for a subsequent hospitalization for hypoglycemia and the variable was 
subsequently removed from the analysis.  
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Table 11:  Descriptive characteristics and exposures of cases and controls 
Covariate Controls 
(n=10,520) 
 
Cases (n=2,630) 
 
Total (n=13,150) 
 
Mean (SD) 
Age at cohort entry 
 63.2  (13.1) 64.4 (14.3) 63.6 (13.4) 
Age at index 
 71.7 (12.9) 72.8 (14.1) 71.9 (13.2) 
Follow up time (years) 
 7.8 (4.9) 7.8 (4.9) 7.8 (4.9) 
n (%) 
Sex 
Male 5,548 (52.7) 1,387 (52.7) 6,935 (52.7) 
Diabetes Medications received in the exposure period (180 days prior to the index date) 
Insulin  2,716 (25.8) 1,359 (51.7) 4,075 (31.0) 
High risk oral hypoglycemic 2,541 (24.2) 826 (31.4) 3,367 (25.6) 
Low risk oral hypoglycemic 2,516 (23.9) 185 (7.0) 2,701 (20.5) 
No drugs  2,747 (26.1) 260 (9.9) 3,007 (22.9) 
Location of residence at index date 
Urban 6,616  (62.9) 1,576 (59.9) 8,192 (62.3) 
Rural 3,809 (36.2) 1,027 (31.1) 4,836 (36.8) 
Missing 95 (0.9) 27 (1.03) 122 (0.93) 
At least one outpatient claim for hypoglycemia in the exposure period (180 days prior to the index date) 
Yes  77 (0.7) 335 (12.7) 412 (3.1) 
Number of outpatient physician claims in the exposure period (180 days prior to the index date) 
0-3 3,593 (34.2) 479 (18.2) 4,072 (30.9) 
4-6 2,810 (26.7) 562 (21.4) 3,372 (25.6) 
7-10 2,171 (20.6) 630 (22.5) 2,801 (21.3) 
≥11 1,946 (18.5) 959 (26.4) 2,905 (22.1) 
At least one specialist claim for diabetes in the exposure period (180 days prior to the index date) 
Yes  516 (4.9) 191 (7.3) 707 (5.4) 
Charlson Comorbidity Index in the 1-year period prior to the index date 
Score of 0 8,156 (77.5) 1,120 (46.0)) 9,366 (71.2) 
1 to 4 2,086 (19.8) 1,076 (40.9) 3,162 (24.0) 
5 or more 278 (2.6) 344 (13.1) 622 (4.7) 
 
45 
In the 180 days preceding the index date, 63% of cases received at least one test strip 
dispensation compared to 51.3% of controls (Table 12).  
Table 12:  Test strip dispensations in the 180 days prior to index (main analysis) 
 Controls 
n (%) 
Cases 
n (%) 
Total 
n (%) 
Test strip dispensation 5,393 (51.3) 1,657 (63.0) 7,050 (53.6) 
 
Substantial clinical differences between cases and controls were found in the overall cohort of 
diabetes patients.  Due to the high degree of heterogeneity, we elected not to proceed with modelling in 
the overall diabetes cohort.  Rather, the case-control analysis was repeated in two nested subgroups 
expected to consist of more homogeneous populations: patients using insulin (representing those at 
highest risk of developing hypoglycemia) and also a subgroup of patients taking low-risk oral 
hypoglycemic medications only (representing those at lowest risk of developing hypoglycemia). 
Insulin Subgroup 
 
Patients with at least one prescription claim for insulin within a year of their cohort entry date 
made up the insulin subgroup (n=10,617). During a mean follow-up of 7.3 years, 8.3% of the insulin 
user subgroup (884/10,617) was hospitalized for hypoglycemia.  Of these, 79 individuals were 
excluded because their hypoglycemic event took place within the first 180 days of cohort entry.  Thus, 
805 cases were matched to 4 controls (with the exception of 1 case for which only 2 suitable controls 
could be identified) for a total sample of 4,023 subjects. The mean age of the overall insulin subgroup 
was 57.1 years (SD 18.3) at cohort entry and 52.1% of subgroup members were male.    
 In the 180 days preceding the index date, 88% of subgroup members received at least one 
prescription for insulin (Table 13).  Most were receiving insulin therapy alone, however approximately 
18% were receiving both insulin and an oral hypoglycemic agent.  Intensity of insulin usage (as 
estimated in units/day) [77] was similar between cases and controls.  Cases had more outpatient 
physician claims than controls, and a higher Charlson Comorbidity Index. Outpatient physician claims 
for hypoglycemia were not included in the final model, due to the potential of being in the causal 
pathway for hypoglycemia hospitalization. 
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Table 13: Descriptive characteristics and exposures of insulin subgroup  
Covariate Controls (n=3,218) Cases (n=805) 
 
Total (n=4,023) 
 
Mean (SD) 
Age at cohort entry 
 58.5 (15.6) 59.6 (16.4) 58.7 (15.7) 
Age at index 
 66.4 (15.5) 67.6 (16.4) 66.7 (15.7) 
Follow up time (years) 
 7.3 (5.1) 7.3 (5.1) 7.3(5.1) 
n (%) 
Sex 
Male 1,690 (52.5) 423 (52.5) 2,113 (52.5) 
Daily insulin consumption [77] in the exposure period (180 days prior to index)  
First quartile  (<29.8 
units/day) 
801 (24.9) 185 (23.0) 986 (24.5) 
Second quartile (29.8-50.3 
units/day) 
781 (24.3) 202 (25.1) 983 (24.4) 
Third quartile (50.3-77.8 
units/day) 
805 (25.0) 212 (26.3) 1,017 (25.2) 
Fourth quartile (>77.8 
units/day) 
831 (25.8) 206 (25.6) 1,037 (25.7) 
Diabetes medications received in the exposure period (180 days prior to index date) 
Insulin alone 2,247 (69.8) 613 (76.2) 2,860 (71.1) 
Insulin + high risk oral 
hypoglycemic 
68 (2.1) 24 (2.9) 92 (2.3) 
Insulin + low risk oral 
hypoglycemic 
507 (15.8) 115 (14.3) 622 (15.4) 
Oral hypoglycemic only 170 (5.3) 21 (2.6) 191 (4.7) 
No drugs  226 (7.0) 32 (4.0) 258 (6.4) 
Location of residence at index date 
Urban 2,061 (63.9) 491 (60.6) 2,552 (63.4) 
Rural 1,157 (35.0) 314 (38.4) 1,471 (35.6) 
Missing 6 (0.1) <6 *  
At least one outpatient physician claim for hypoglycemia in exposure period (180 days prior to the index date)+ 
Yes  62  (1.9) 129 (16.0) 191 (4.8) 
Number of outpatient physician claims in the exposure period (180 days prior to the index date) 
0-3 975 (30.3) 165 (20.5) 1,140 (28.3) 
4-6 848 (26.3) 158 (19.6) 1,006 (25.0) 
7-10 723 (22.5) 204 (24.3) 927 (23.0) 
≥11 672 (20.9) 277 (34.5) 950 (23.6) 
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At least one specialist claim for diabetes in the exposure period (180 days prior to index date) 
Yes  317 (9.8) 84 (10.4) 401 (10.0) 
Charlson Comorbidity Index in the 1-year period prior to index date 
Score of 0 2,367 (73.6) 377 (46.8) 2,744 (68.2) 
1 to 4 731 (22.7) 334 (41.5) 1,065 (26.5) 
5 or more 120 (3.7) 94 (11.7) 214 (5.3) 
*Indicates that the frequency of the variable was less than 6 and cannot be reported 
+  Variable not included in final model as it was considered to be an intermediate factor between the independent variable and the outcome 
 
Model Results 
In the 180 days preceding the index date, 77% of cases and 73% of controls received at least 
one dispensation for test strips (Table 14). In univariate analysis, test strip dispensation was associated 
with a significant increase in the odds of hospital admission for hypoglycemia (unadjusted OR 1.25, 
95% CI [1.04,1.50], p=0.02)(Table 15).  However, after covariate adjustment, test strip dispensations 
became non-significant (adjusted OR 1.08, 95% CI [0.88,1.31], p=0.48). 
The model was tested for pre-specified interactions between test strip dispensation and clinical 
characteristics.  No significant interaction was found between test strip dispensation and diabetes 
therapy (p=0.96), between test strip dispensation and Charlson Comorbidity Index (p=0.31), or test 
strip dispensation and intensity of insulin use (p=0.93).   
 
Table 14: Test strip dispensations within 180 days of index (Insulin subgroup) 
 Controls 
n (%) 
Cases 
n (%) 
Total 
n (%) 
Test strip dispensation 2350 (73.0) 620 (77.0) 2970 (73.8) 
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Table 15:  Predictors of hospitalizations for hypoglycemia (insulin subgroup)  
Covariate Unadjusted OR 95% CI p-value Adjusted OR* 95% CI  p-value 
Test strip dispensation in the exposure period (180 days prior to index date) 
No  1.0      
Yes  1.25 1.04-1.50 0.02 1.08 0.88-1.31 0.48 
Diabetes Medications received in the exposure period (180 days prior to index date) 
No drugs 1.0      
Oral 
hypoglycemic 
alone 
0.89 0.50-1.61 0.71 0.81 0.44-1.49 0.50 
Insulin + Low 
risk oral 
hypoglycemia 
1.65 1.07-2.53 0.02 1.78 1.09-2.92 0.02 
Insulin + High 
risk oral 
hypoglycemic 
2.58 1.40-4.73 <0.01 2.42 1.26-4.65 0.01 
Insulin alone 1.99 1.35-2.94 <0.01 2.25 1.44-3.52 <0.01 
Estimated daily insulin consumption (units/day) in the exposure period (180 days prior to index date) 
<29.8 1.0      
29.8-50.3 1.13 0.90-1.41 0.30 0.87 0.67-1.14 0.31 
50.3-77.8 1.15 0.92-1.44 0.23 0.87 0.67-1.14 0.32 
>77.8 1.08 0.86-1.36 0.50 0.81 0.62-1.06 0.13 
Location of residence at index date 
Rural 1.0      
Urban 0.89 0.75-1.03 0.11 0.85 0.72-1.01 0.07 
Number of outpatient physician claims in the exposure period (180 days prior to index date) 
0-3 1.0      
4-6 1.15 0.91-1.47 0.24 0.98 0.76-1.25 0.85 
7-10 1.76 1.39-2.22 <0.01 1.36 1.06-1.75 0.01 
≥11 2.61 2.08-3.27 <0.01 1.76 1.37-2.26 <0.01 
Specialist claim for diabetes in the exposure period (180 days prior to index date) 
No  1.0      
Yes  1.07 0.83-
1.39 
 0.62 0.87 0.66-1.15 0.33 
Charlson Comorbidity Index in the 1-year period prior to the index date 
Score of 0 1.0      
1 to 4 2.99 2.51-3.57 <0.01 2.69 2.24-3.23 <0.01 
5 or more 5.43 4.00-7.38 <0.01 4.46 3.24-6.14 <0.01 
*Adjusted for all covariates in the table AIC =2334.86 BIC=2429.37 
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Sensitivity analyses that were pre-specified for the main analysis were subsequently conducted 
within the insulin subgroup. In the first sensitivity analysis, cases that had been previously excluded 
from the insulin subgroup analysis due to their hypoglycemic event occurring in the first 180 days after 
cohort entry were entered into the analysis.  This resulted in a study cohort of 4,418 individuals (884 
cases, 3,534 controls).  In this analysis, the distribution of covariates and subsequent model results 
were consistent with that of the primary analysis (unadjusted OR for strip use 1.24, 95% [CI 1.04,1.48], 
p= 0.02; adjusted OR 1.08, 95%CI [0.89,1.31], p=0.42).   In a second sensitivity analysis, exposures 
were characterized in the 90 days prior to the index date.  Again, test strip dispensation was not a 
significant predictor of hypoglycemia hospitalizations after covariate adjustment (unadjusted OR 1.28, 
95% CI [1.09,1.52], p<0.01; adjusted OR 1.14, 95% CI  [0.95,1.35], p=0.16).  A third sensitivity 
analysis with diabetes therapy classified according to the therapeutic class of hypoglycemic agent could 
not be carried out due to the low numbers of patients on oral hypoglycemic agents in this subgroup. 
In a final sensitivity analysis, test strip dispensation was categorized based on the number of 
strips dispensed in the 180 days prior to the index date.  Test strip dispensations were categorized based 
on approximate quartiles of use as follows:  1) no test strips dispensed; 2) 1-100 test strips dispensed; 
3) 101-200 test strips dispensed; or 4) more than 200 test strips dispensed.  In the univariate logistic 
model, the risk of hospitalization for hypoglycemia did not differ between those receiving 1 to 100 or 
101 to 200 strips and those not receiving test strips in the 180 days prior to index (Table 16).  However, 
receiving more than 200 test strips was associated with an increased risk for hospitalization for 
hypoglycemia when compared to those not receiving test strips. After adjusting for covariates in the 
main effect model, this effect became non-significant. The model also included two-way interaction 
effects between test strip use and (a) mode of diabetic therapy, (b) Charlson Comorbidity Index, and (c) 
intensity of insulin use (by DACON quartile), of which none were significant (p=0.87, p=0.71, and 
p=0.65, respectively). 
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Table 16:  Predictors of hospitalizations for hypoglycemia (insulin subgroup) with test strip use 
in the 180 days prior to index categorized according to quartiles of use 
Number of 
test strips 
dispensed 
n (%) Unadjusted OR 95% CI p-value Adjusted 
OR* 
95% CI p-value 
0  1,053 
(26.2) 
1.0   1.0  
1-100  690 
(17.2) 
0.99 0.77-1.29 0.99 0.89 0.68-1.17 0.42 
100-200 550 
(13.7) 
1.10 0.84-1.44 0.48 0.90 0.68-1.20 0.47 
>200  1,730 
(43.0) 
1.43 1.17-1.75 <0.01 1.23 0.99-1.53 0.06 
* Adjusted for covariates in Table 6 
Low risk oral hypoglycemic agent subgroup 
The next subgroup analysis was conducted in patients receiving low-risk hypoglycemic agents. 
Individuals were included in the low-risk oral subgroup if they had at least one prescription claim for 
an oral hypoglycemic agent with a low risk of causing hypoglycemia within 1 year of cohort entry. 
Patients were followed until the earliest of: receiving insulin or a high-risk oral hypoglycemic agent, 
loss of coverage, death, or end of follow-up period.  During a mean follow-up of 3.8 years, 0.2% of the 
low-risk oral hypoglycemic user subgroup (113/47,501) was hospitalized for hypoglycemia. The mean 
age of the low-risk hypoglycemic user subgroup was 64.5 years (SD 11.7) at cohort entry and 50.7% of 
subgroup members were male.    
Of the 113 subgroup members that were hospitalized for hypoglycemia (i.e. cases), 38 were 
excluded as their event occurred within the first 180 days of cohort entry.  The remaining 75 cases were 
successfully matched to 4 controls. Approximately 80% of subgroup members had a dispensation for a 
low-risk oral hypoglycemic agent during the 180 days prior to index, while approximately 20% did not 
have a dispensation for any diabetic medications during the exposure period (Table 17).  Similar to the 
previous analyses, cases were more likely to have a higher Charlson Comorbidity Index than controls 
and visited their physicians more often. 
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Table 17: Descriptive characteristics and exposures of low risk oral hypoglycemic user subgroup  
Covariate Controls (n=300) Cases (n=75) 
 
Total (n=375) 
 
Mean (SD) 
Age at cohort entry 
 66.1 (12.3) 67.2 (13.0) 66.3 (12.4) 
Age at index 
 71.7 (12.7) 72.9 (13.8) 72.0 (12.9) 
Follow up time (years) 
 5.6 (4.0) 5.7 (4.0) 5.6 (4.0) 
n (%) 
Sex 
Male 136 (45.3) 34 (45.3) 170 (45.3) 
Diabetes medications received in the exposure period (180 days prior to the index date) 
Low risk oral 
hypoglycemic 
241 (80.3) 57 (76.0) 298 (79.5) 
No drugs  59 (19.7) 18 (24.0) 77 (20.5) 
Location of residence 
Urban 174 (58.0) 47 (62.7) 221 (58.9) 
Rural 126 (42.0) 28 (37.3) 154 (41.1) 
At least one outpatient physician claim for hypoglycemia in the exposure period  (180 days prior to the 
index date)+ 
Yes  0 (0) <6* * 
Number of outpatient physician claims in the exposure period  (180 days prior to the index date)° 
0-3 109 (36.3) 11 (14.6) 120 (32.0) 
4-6 88 (29.3) 17 (22.7) 105 (28.0) 
7-10 52 (17.3) 17 (22.7) 69 (18.4) 
≥11 51  (17.0) 30 (40.0) 81 (21.6) 
At least one specialist claim for diabetes in the exposure period  (180 days prior to the index date) 
Yes  8 (2.7) <6* * 
Charlson Comorbidity Index in the 1-year period prior to the index date 
Score of 0 240 (80.0) 32 (42.7) 272 (72.5) 
1 to 2 42 (14.0) 13 (17.3) 55 (14.7) 
3 or more 18 (6.0) 30 (40.0) 48 (12.8) 
+ Variable not included in model due to zero cell value for controls 
*Censored due to small cell size 
°Variable not included in model due to zero cell sizes 
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Table 18:  Test strip dispensations within 180 days of index (low risk oral hypoglycemic user subgroup) 
 Controls 
N (%) 
Cases 
N (%) 
Total 
N (%) 
Test strip dispensation 104 (34.7) 29 (38.7) 133 (35.5) 
 
Model Results 
In the 180 days preceding the index date, 38.7% of cases and 34.7% of controls received at least one 
dispensation for test strips (Table 18).  Test strip dispensation was not a significant predictor of hospital 
admission for hypoglycemia (adjusted OR 1.04, [95% CI 0.55,1.94], p= 0.91) (Table 19).  Interactions 
between test strip use and disease-related factors were non-significant (p=0.16 for test strip use and 
Charlson Comorbidity Index), however a statistically significant interaction between test strip use and 
diabetic therapy was noted (p=0.03), indicating that risk of hospitalization for hypoglycemia was 
reduced in low risk OHA users with a test strip dispensation when compared to non-drug users with a 
test strip dispensation. This interaction may represent a spurious statistically significant result due to 
small sample size given the wide confidence interval (OR 0.17, [95% CI 0.04, 0.62].  The clinical 
significance of this interaction was also deemed questionable as patients not on diabetic therapy should 
have a negligible risk of experiencing hypoglycemia, regardless of blood glucose test strip use.   
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Table 19:  Predictors of hospitalizations for hypoglycemia  (low risk oral hypoglycemic user subgroup) 
Covariate Unadjusted 
OR 
95% CI p-value Adjusted 
OR* 
95% CI p-value 
Test strip dispensation in the exposure period (180 days prior to index date) 
No 1.0      
Yes 1.19 0.70-2.03 0.51 1.04 0.55-1.94 0.91 
Diabetes Medications received in the exposure period (180 days prior to index date) 
No drugs 1.0      
Low risk oral 
hypoglycemic 
0.73 0.38 -1.43 0.36 0.52 0.24 -1.14 0.10 
Location of residence 
Rural 1.0      
Urban 1.22 0.72 -2.04 0.46 1.03 0.57-1.89 0.92 
Number of outpatient physician visits in the exposure period  (180 days prior to the index date)° 
0-3 1.0        
4-6 1.82 0.80-4.10 0.15 1.90 0.78-4.63 0.16 
7-10 3.29 1.46-7.42 <0.01 2.28 0.91-5.70 0.09 
≥11 5.70 2.64-12.34 <0.01 3.12 1.25 -7.77 0.02 
Charlson Comorbidity Index in the 1-year period prior to the index date 
Score of 0 1.0        
1 to 2 2.47 1.16-5.27 0.02 1.99 0.90-4.38 0.09 
3 or more 13.00 6.03-28.02 <0.01 10.01 4.39-22.83 <0.01 
*AIC=195.40 BIC=226.82 
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Chapter 5: Discussion 
Saskatchewan health-administrative databases were used to construct a population-based, 
retrospective study examining trends in blood glucose test strip utilization and their impact on 
hospitalization for hypoglycemia.  All measures of blood glucose test strip use increased over the 
course of the study (i.e. from 1996 to 2014).  In contrast, no obvious trends in hospitalizations for 
hypoglycemia were observed until 2007, when a clear decreasing rate persisted until 2014.  As a result, 
no association was found province-wide use of blood glucose test strip use and hospitalization rates for 
hypoglycemia.  Similarly, blood glucose test strip use was not associated with a reduced risk of 
hospitalizations for hypoglycemia using a case-control study design.  This finding was consistent 
among patients using insulin and those using low-risk oral hypoglycemic agents. 
 All measures of blood glucose test strip utilization increased over the study period in a manner 
consistent with previously published studies [10].  The number of dispensed test strips increased 
approximately 300% from 1996 to 2010, while the number of test strip users increased by over 150% 
during the same time period. In Manitoba, blood glucose test strip use increased by 170% from 2000 to 
2013 [78].  In Ontario, blood glucose test strip use increased 250% from 1997 to 2008 ([79]. In the 
current study however, test strip utilization stabilized from 2010 to 2014, presumably due to a 
heightened awareness of test strip over-use reported in numerous publications questioning the clinical 
utility and cost effectiveness of SMBG ([7, 8, 80]. A similar trend was also identified in British 
Columbia.  Despite an overall 28% increase in test strip utilization from 2004 to 2012, test strip use 
decreased by 4% per year from 2010 to 2012 [81].  Beginning in 2013, provinces across Canada began 
implementing restriction limits for blood glucose test strip reimbursement.  In 2013, Ontario imposed 
limits that were associated with a 20% reduction in costs [82]. British Columbia and Saskatchewan 
imposed limits starting in 2015 [83] [22].  To date, no published studies have reported cost savings in 
either of those provinces.    
 There was no clear trend in hospitalizations for hypoglycemia between 1996 and 2005; 
however, a decreasing trend was observed between 2008 and 2014 (annual decrease -17.9/year; 
p<0.01).  One of the most striking results was a substantial spike in hospitalizations for hypoglycemia 
between 2005 and 2006.  Reasons for this abrupt change remain unclear.  Changes in coding practices 
were not likely the cause because Saskatchewan changed its hospital discharge coding system in 2001-
2002 (i.e., from ICD-9 to ICD-10-CA) [45].  Also, the elevated trend between 2005 and 2006 persisted 
when only the most responsible diagnosis code or codes in the first two diagnostic positions were used 
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to identify hypoglycemia. However, trends in the individual diagnosis codes for hypoglycemia were 
not tracked over the study period, so it was not possible to determine which (if any) diagnostic codes 
were specifically contributing to the increase in recorded events. Finally, no major changes in 
hypoglycemic drug or insulin formulary listings occurred from 2006 to 2008 [22].   
 Changes in the incidence of hypoglycemia hospitalizations may have been a result of 
diabetes management strategies rather than coding practices. The DC guidelines published in 2003 
recommended aggressive glycemic targets for most patients [84, 85], which may have resulted in the 
increased number of hypoglycemia hospitalizations between 2006 and 2007.  In 2008, the ACCORD 
trial demonstrated that tighter glycemic control in patients with a long-standing history of diabetes or 
cardiovascular disease resulted in increased mortality[15].  The DC guidelines released the same year 
recommended less stringent glycemic targets[85] which may have translated into less aggressive blood 
glucose management (thereby reducing the risk of hypoglycemia in potentially high risk patients).   As 
well, new insulin products (such as long and rapid-acting insulin analogues) that may result in less 
hypoglycemia [86] became widely used due to formulary inclusion status in 2009 and 2010 [22], which 
also may have explained the decline in hospitalizations for hypoglycemia. Of note, the number of 
physician visits for hypoglycemia (which greatly outnumbered hospitalizations for hypoglycemia) did 
not exhibit the same trend over study period. In addition, this trend was not observed in Ontario where 
ED visits and hospitalizations for hypoglycemia have exhibited a general declining trend in several 
studies [42, 43].  
 Although available emergency department data was limited to visits occurring in 
Saskatchewan’s largest urban hospitals within a three-year time span (2012 to 2014), it appears that 
only a fraction of all patients presenting to hospital with hypoglycemia (15%) are admitted for at least 
one night. Thus, it is highly possible that changes in the clinical management of these patients in the 
emergency department could have impacted the observed rate of hospitalization.  However, due to the 
short time frame of available data, it was not possible to determine if this preliminary trend was 
consistent over the study period.  In Ontario, emergency department visits for hypoglycemia exhibited 
an overall declining trend over a similar time frame [42, 43].  Therefore, the impact of emergency 
department visits for hypoglycemia on hospitalization rates remains unanswered.  
 Population-wide test strip utilization was not associated with hospitalizations for hypoglycemia 
in this study.  A similar finding from Ontario has recently been published.  Gomes and colleagues 
reported no significant changes in emergency department hypoglycemia visits following test strip 
quantity limit implementation [43]. Follow-up was limited to 18 months only so longer-term studies 
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should be conducted to confirm these observations. In the current study, the association between test 
strip utilization and hypoglycemia endpoints was directly tested over an 18-year time frame and in a 
broader segment of the diabetic patient population. This study provides additional, longer-term 
evidence to suggest that blood glucose test strip use does not affect hypoglycemia healthcare utilization 
rates. 
 The association between test-strip use and hypoglycemia hospitalizations was also examined at 
the patient level using a nested case-control study design.  The initial cohort was comprised of all 
patients with diabetes; however, substantial differences in clinical characteristics between cases and 
controls were observed despite matching on age, sex, and cohort entry date.  Therefore, the study was 
repeated within two subgroups: insulin users and patients receiving low-risk oral hypoglycemic 
medications.  Both groups were expected to demonstrate a more uniform risk of hypoglycemia (insulin 
users = high risk versus oral hypoglycemic patients = low risk).  Among insulin users, test strip use was 
associated with an increased risk of hospitalization in unadjusted analysis (OR 1.25, 95% CI 
[1.04,1.50], p=0.02) but this association became non-significant after covariate adjustment (adjusted 
OR 1.08, 95% CI [0.88,1.31], p=0.48).  This finding was consistent across several pre-specified 
sensitivity analyses and the relationship between test strip use and hospitalizations for hypoglycemia 
did not change according to the intensity of insulin use (p=0.93).  Similar results were observed when 
patients were categorized by the number of test strips dispensed during the exposure period.  In the 
unadjusted analysis, no differences were observed between patients in the three lowest exposure 
categories of test strip use; however the highest category of test strip use (i.e. more than 200 strips 
dispensed in the 180 days prior to index) had an increased risk of hypoglycemia hospitalization.  Again, 
this risk became non-significant after covariate adjustment.  In low-risk oral hypoglycemic users, test 
strip use was not associated with hospital admission for hypoglycemia in both unadjusted and adjusted 
analyses (p=0.51 and p=0.91, respectively).  
 An increased risk of hypoglycemic events among frequent test strip users has been reported in 
previous studies reporting unadjusted results [7, 8, 26-28].  Because covariate adjustment attenuated the 
risk estimate, it is likely the crude association resulted because patients who are already at a higher risk 
of developing hypoglycemia perform testing more frequently than those at lower risk [7, 8, 41].   None 
of the risk estimates for blood glucose testing indicated a protective effect against hypoglycemia 
hospitalizations.  However, it should be noted that very high levels of test-strip use were observed in 
individuals at greatest risk of developing hypoglycemia; approximately three-quarters of the insulin 
user cohort had a dispensation for test strips in the exposure period.  As a result, it is possible that a 
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lower threshold of test strip use does increase the risk for hypoglycemia but very few patients at 
increased risk of developing hypoglycemia in current practice reach it. Our findings suggest that 
patients exhibiting low levels of test strip use in the current context of diabetes management do not 
experience a high risk of hypoglycemia.    
 Large differences between cases and controls observed in this study have also been reported 
previously [31, 40].  Cases in the present study were more likely to use insulin or high risk oral 
hypoglycemic agents, had a higher comorbidity burden, and had more outpatient physician visits. In 
fact, previous outpatient claims for hypoglycemia were excluded from the final model because more 
than a quarter occurred within one day of the index event (i.e., hospitalization for hypoglycemia).  As a 
result, this variable appeared to represent the actual case event rather than serve as an independent risk 
factor.   
 
Strengths and Limitations 
The strengths of this study include its population-based design that captured virtually all 
residents of Saskatchewan regardless of income or employment status.  It has previously been 
demonstrated that hospital discharge records are a sensitive and specific measure of hypoglycemia 
hospitalizations [45, 49].  This endpoint is clinically important from both a resource and patient safety 
perspective.  However, several limitations should be noted.  Individuals with federal drug coverage 
(most notably registered First Nations), were not included in this study as their test strip utilization 
could not be captured prior to 2006.  Although the high prevalence of diabetes in First Nations has been 
well-established [87], to our knowledge the comparable risk of hypoglycemia has not been defined in 
this patient population.  This may limit the generalizability of this study, as its findings may not be 
comparable in this patient population.  Test strip utilization endpoints were based solely on dispensing 
information; patients may not have actually used the test strips dispensed or may have purchased test 
strips without a prescription.  Numerous factors that have been shown to increase the risk for 
hypoglycemia could not be accounted for, including type of diabetes, precipitating events (e.g. dietary 
indiscretions, exercise, minor illness), degree of glycemic control, previous episodes of hypoglycemia, 
renal function, and cognitive status [30, 32, 34, 36].  The impact of these factors, plus other possible 
unmeasured confounders may change the relationship between test strip use and hospitalizations for 
hypoglycemia beyond the findings of this study. In addition, severe hypoglycemic events that did not 
result in hospitalization, such as events occurring at home, or those treated solely by emergency 
medical services or the emergency department could not be captured throughout the study period. 
Previous studies have suggested only 10% of severe episodes of hypoglycemia result in hospital 
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treatment [32, 34], therefore this study may only represent a small proportion of hypoglycemic events.  
Finally, hypoglycemia hospitalization rates changed dramatically during the observation period and 
could not be explained with existing sources.   
 
 
Chapter 6: Conclusion 
 
Population-wide use of blood glucose test strips is not associated with the rate of 
hospitalizations for hypoglycemia.  The province-wide increase in test strip utilization over the study 
period did not translate into a reduction of hospitalizations for hypoglycemia over the same time frame.  
At the individual level, blood glucose test strip use did not reduce the risk of hospitalization for 
hypoglycemia in diabetic patients both at high and low risk of developing drug-induced hypoglycemia.  
This study adds to the body of evidence that suggests test strip use has a marginal impact on patient 
outcomes in most diabetic patients, and that policies that limit the reimbursement of blood glucose test 
strip are unlikely to be detrimental in terms of effects on patient safety. 
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